Podcasts about medtronic diabetes

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new Austrailian study aims to prevent type 1, the new twiist pump will integrate with Eversnse CGM as well as Libre, diabetes deaths are down in the US, Dexcom U is looking for college athletes, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A world-first human trial of a drug designed to treat the underlying cause of type 1 diabetes has begun in Australia. University of Queensland researcher Ranjeny Thomas said the experimental drug — dubbed ASITI-201 — was designed to retrain the immune system so it no longer attacks the insulin-producing pancreatic cells, known as beta cells. The drug, given as an injection under the skin, combines fragments of a protein found in the beta cells of people with type 1 diabetes and vitamin D to calm the immune response. She said if effective, the drug would initially be given to patients with type 1 diabetes as soon as possible after diagnosis to preserve remaining pancreatic cells and reduce the amount of insulin needed. But eventually, if screening programs can be developed to pick up people at risk of developing type 1 diabetes, it may be possible to "prevent the progression of the disease altogether". The first in-human trial of 36 participants will test the safety of the drug, but blood tests will also determine the impact of the therapy on a patient's immune system and glucose tolerance. https://www.abc.net.au/news/2025-04-29/type-1-diabetes-drug-trial-auto-immune-disease-science/105223022 XX   Diabetes deaths in the U.S. have fallen to some of the lowest rates in years, according to new preliminary figures published by the Centers for Disease Control and Prevention, reversing a surge in mortality that was seen during the COVID-19 pandemic.   There were 26.4 deaths per 100,000 people from diabetes, according to early death certificate data for the third quarter of 2024 published this month by the CDC's National Center for Health Statistics.   Death rates from diabetes peaked in 2021, according to CDC figures, at 31.1 deaths per 100,000 people for that year. Diabetes was the eighth leading cause of death in 2021. The CDC says the link between COVID-19 and diabetes may be to blame for that increase.   "Data show an increase in mortality rates for all people during the COVID-19 pandemic, and research shows that people with underlying conditions, including diabetes, are more likely to become very sick from COVID-19 and have a higher risk of hospitalization and death," Christopher Holliday, head of the CDC's Division of Diabetes Translation, told CBS News in a statement.   Holliday added that research shows the pandemic may also have made it harder for Americans to properly manage the disease, ranging from interruptions to physical activity to disruptions to routine medical care diagnosing and treating the disease.   https://www.cbsnews.com/news/diabetes-deaths-lowest-levels-years-early-cdc-figures/ XX Big news for the Eversense CGM – they have their first pump partner. Sequel Med Tech says the twist pump will integrate with Senseonics Eversense 365 continuous glucose monitor (CGM). This collaboration would make twiist the first AID system compatible with Eversense 365, the world's first and only one-year CGM. Sequel and Senseonics say they have already started their work to integrate the latest-generation, 365-day implantable sensor with twiist. They expect to make the integrated offering available in the third quarter of this year. This marks the second CGM integration for Sequel, which partnered with Abbott and its FreeStyle Libre platform earlier this year. This week we also got a peek at the packaging and delivery of the twist as the first people posted about wearing it. We'll follow up and learn more about this newest insulin pump in the us. Senseonics, meanwhile, brought the first year-long CGM to market last year, launching Eversense 365 with its global distribution partner, Ascensia Diabetes Care, in October 2024. The system also received clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems. https://www.drugdeliverybusiness.com/sequel-senseonics-integrate-cgm-insulin-pump/ XX Medtronic has announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync sensor for use with the MiniMed 780G system. With this approval, the MiniMed 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection technology with both the Guardian 4 sensor and Simplera Sync sensor.   The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard or overtape and features a simple, two-step insertion process. It is the company's newest addition to its CGM portfolio, which expands options and provides greater flexibility for users.   The MiniMed 780G system's adaptive algorithm automatically anticipates, adjusts, and corrects glucose levels every 5 minutes, 24/7 – working around the clock so users can focus on what matters. It's the only system featuring Meal Detection technology, which detects rising sugar levels and delivers more insulin as needed to help users keep glucose levels in range more often – even when users occasionally forget to dose insulin for snacks or meals or underestimate their carbs.   The system uses a “treat to target” approach and flexible glucose targets as low as 100 mg/dL, which, combined with its adaptive algorithm allows it to more closely mirror the glucose levels of someone not living with diabetes.   Real-world data of the system shows global users consistently achieve time in range above international targets of 70% when using optimal settings (active insulin time of two hours and 100 mg/dL target glucose). It is also the only system that works with the world's only infusion set that lasts up to 7 days so that users only have to change their infusion set once per week and can experience 96% fewer injections compared to multiple daily injections.   “We're committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day,” said Que Dallara, EVP and president of Medtronic Diabetes. “Our MiniMed 780G system delivers advanced diabetes technology for so many around the world, and we're excited to continue evolving this experience with expanded CGM options —including our Simplera Sync sensor, which we look forward to bringing to people living with diabetes in the U.S.”   A limited launch of the Simplera Sync sensor will begin in the U.S. in the fall of 2025. Today, the MiniMed 780G system can be used with the Guardian 4 sensor.   Like this:https://med-techinsights.com/2025/04/29/simplera-sync-sensor-for-minimed-780g-now-fda-approved/ XX Front office changes at Insulet.. The former head of Johnson & Johnson's worldwide medtech business, Ashley McEvoy will take over as president and CEO from Jim Hollingshead, who has led Insulet since 2022. In its announcement of the leadership change, Insulet said that Hollingshead and the company mutually agreed to part ways, effective immediately. McEvoy served as worldwide medtech chairman at J&J from 2018 until her departure in late 2023, the culmination of nearly 30 years at the company and several executive roles—including president of its Ethicon division and group chairman of vision and diabetes care. Since then, she has also served as a board member at Procter & Gamble. https://www.fiercebiotech.com/medtech/insulet-taps-former-jj-medtech-head-ashley-mcevoy-be-ceo XX New free mobile game launched this week to make type 1 diabetes onboarding faster easier and less overwhelming. It's called Level One.. created by Level Ex (Powered by Relevate Health), the studio behind award-winning medical games for medical professionals. Level Ex CEO Sam Glassenberg created the game after a – quote  - brutal onboarding experience when his daughter was diagnosed five years ago He says  It took a year to understand how to manage this disease. So we fixed it. We built a game that can train your brain to do it in a matter of hours." The game is launching in partnership with leading diabetes organizations Beyond Type 1 and Breakthrough T1D Play, who are integrating Level One into their outreach and educational campaigns to support newly diagnosed families worldwide. Download Level One on the App Store: https://apps.apple.com/us/app/level-one-a-diabetes-game/id6739605694 Learn more: https://playlevelone.com   https://www.prnewswire.com/news-releases/level-ex-launches-level-one-a-free-mobile-game-to-redefine-type-1-diabetes-onboarding-302440929.html XX   Collagen is widely recognized for its role in maintaining healthy skin, but its importance extends far beyond that. As the most abundant protein in the human body, collagen provides essential structure and support to nearly all tissues and organs.   Now, researchers at Carnegie Mellon's Feinberg Lab have made a major breakthrough using their novel Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D bioprinting technique. This method enables the precise printing of soft, living cells and tissues. Leveraging this technology, the team successfully created the first-ever microphysiologic system, also known as a tissue model, constructed entirely from collagen. This advancement opens new possibilities for studying disease and engineering tissue therapies, including potential treatments for conditions like Type 1 diabetes.   Traditionally, small-scale models of human tissue, referred to as microfluidics, organ-on-chip devices, or microphysiologic systems, have been fabricated using synthetic materials such as silicone rubber or plastics. These materials were necessary due to limitations in earlier manufacturing techniques. However, because they are not biologically native, they fail to fully replicate natural tissue environments, restricting their effectiveness in biomedical research and therapeutic development.   “Now, we can build microfluidic systems in the Petri dish entirely out of collagen, cells, and other proteins, with unprecedented structural resolution and fidelity,” explained Adam Feinberg, a professor of biomedical engineering and materials science & engineering at Carnegie Mellon University. “Most importantly, these models are fully biologic, which means cells function better.”   Building Complex Tissues with FRESH Bioprinting In new research published in Science Advances, the group demonstrates the use of this FRESH bioprinting advancement, building more complex vascularized tissues out of fully biologic materials, to create a pancreatic-like tissue that could potentially be used in the future to treat Type 1 diabetes. This advancement in FRESH bioprinting builds on the team's earlier work published in Science, by improving the resolution and quality to create fluidic channels that are like blood vessels down to about 100-micron diameter.   “There were several key technical developments to the FRESH printing technology that enabled this work,” described Daniel Shiwarski, assistant professor of bioengineering at the University of Pittsburgh and prior postdoctoral fellow in the Feinberg lab. “By implementing a single-step bioprinting fabrication process, we manufactured collagen-based perfusable CHIPS in a wide range of designs that exceed the resolution and printed fidelity of any other known bioprinting approach to date. Further, when combined with multi-material 3D bioprinting of ECM proteins, growth factors, and cell-laden bioinks and integration into a custom bioreactor platform, we were able to create a centimeter-scale pancreatic-like tissue construct capable of producing glucose-stimulated insulin release exceeding current organoid based approaches.” https://scitechdaily.com/scientists-bioprint-living-tissues-that-could-revolutionize-diabetes-treatment/ XX Another study showing the blood sugar benefit of walking after a meal. Skeletal muscle plays a central role in glucose uptake. Exercise stimulates glucose transport into muscle cells through insulin-independent pathways, notably through the action of glucose transporter type 4 (GLUT-4), which is responsible for transporting glucose from blood to skeletal muscles.4 This means that even without a robust insulin response, physical activity can facilitate glucose clearance from the bloodstream. These effects also occur without requiring high-intensity exercise, making postprandial walking accessible to a broad range of individuals, including those with limited exercise tolerance. multiple studies show that starting activity within 30 minutes after a meal is optimal. https://www.news-medical.net/health/Walking-After-Meals-Small-Habit-Big-Metabolic-Gains.aspx XX Dexcom brings back Dexcom U for a 4th years. This is a name, image and license program for college athletes with diabetes and includes a nationwide open call for passionate and inspiring college athletes to join its roster. Now through May 23, athletes, coaches, friends and family members can nominate candidates through an online submission. Those selected, along with the eight returning athletes from last year, will be invited to attend the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. https://www.hmenews.com/article/dexcom-u-returns-for-fourth-season

This week, we interviewed Laura Stoltenberg. Laura is the President and Chief Executive Officer at Cryosa. Laura brings nearly three decades of experience in strategy, business development, and global general management. She has a passion for developing and commercializing novel products to improve the standard of care. Most recently, Laura was Sector Chief Executive at Halma PLC, responsible for $1B in revenue. While at Medtronic, she served as Vice President and General Manager at Medtronic Diabetes and built a new business focused on Type 2 patients. Laura served as Chief Commercial Officer at Exact Sciences Corporation, where she was responsible for developing the global commercial strategy prior to FDA approval. Earlier in her career, she held escalating commercial and leadership roles at General Electric, including leading GE Healthcare's global bone densitometry business and completing a number of acquisitions. Laura earned an MBA at Columbia Business School and bachelor's degrees in electrical engineering and management at Bucknell University.

We're taking a deep dive into Medtronic's InPen with missed meal dose detection. This was approved just a few weeks ago and paves the way for the launch of what they're calling Smart MDI. I'm taking to Madison Smith, Therapy Chief Engineer for MDI Systems at Medtronic Diabetes. She'll explain what's new here, how it all works and what she – as someone who lives with type 1 – would love to see next . This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

Medtronic and Abbott Join Forces: Groundbreaking CGM Partnership for Diabetes Care In this episode of 'Diabetics Doing Things,' we delve into the surprising partnership between industry giants Medtronic and Abbott. On August 7th, they announced their collaboration on a Continuous Glucose Monitoring (CGM) system, combining Abbott's advanced Freestyle Libre 3 technology with Medtronic's insulin delivery devices. We discuss the press releases from both companies, the strategic alignment that led to this partnership, and hear insights from Ali Dianaty, Senior VP at Medtronic Diabetes, and Dr. Anila Bindal, Associate Medical Director at Abbott's Diabetes Care. This episode covers the potential impact on diabetes care, market reactions, and what this means for patients globally. 00:00 Introduction and Episode Overview 00:18 Breaking News: Medtronic and Abbott Partnership 00:53 Reading the Official Press Releases 04:47 Interview with Industry Experts 05:43 Impact on the Diabetes Community 10:14 Future Expectations and Patient Benefits 18:11 Closing Thoughts and Final Remarks

Lou Lintereur, Chief Engineer for automated delivery systems at Medtronic Diabetes, brought his knowledge from working as an aerospace engineer at NASA  to developing technology for those living with diabetes.  He introduces the MiniMed 780G, a closed-loop system that combines an insulin pump and continuous glucose monitor (CGM) with a control algorithm that tailors itself to each patient's unique physiology and Meal Detection technology, which helps manage their blood sugar levels. Patient feedback is essential to the continuing innovation of these hybrid closed-loop tools to manage diabetes. Lou explains, "There are two main challenges we're always trying to deal with, and they kind of compete with each other. One is just the fundamental technology, trying to get the best therapy for the patients and the best outcomes for a long, healthy life where they're feeling good. With respect to diabetes, it's about keeping your blood sugar under as tight a control as possible within a normal glucose range. So that poses the technical challenges of how to design a control system to do that with all the uncertainties of human physiology and so forth." "But on the other side, the systems we make at Medtronic Diabetes are almost consumer products. In order to get the therapy that they need, the patient often has to contribute to the therapy. They need to indicate when they're eating, for example, and then help the system calculate how much they're eating so that they can dose the insulin properly to manage their meals better. It requires some cooperation with the patients. So, on that side of the challenge is, how do you make the system easy enough to use so that the patient can get the best outcomes possible and do as little work as possible? Because the last thing the patient wants to do is be bothered all the time having to manage their therapy." #MedtronicDiabetes #Diabetes #ContinuousGlucoseMonitor #CGM #InsulinPump  medtronicdiabetes.com Download the transcript here

Lou Lintereur, Chief Engineer for automated delivery systems at Medtronic Diabetes, brought his knowledge from working as an aerospace engineer at NASA  to developing technology for those living with diabetes.  He introduces the MiniMed 780G, a closed-loop system that combines an insulin pump and continuous glucose monitor (CGM) with a control algorithm that tailors itself to each patient's unique physiology and Meal Detection technology, which helps manage their blood sugar levels. Patient feedback is essential to the continuing innovation of these hybrid closed-loop tools to manage diabetes. Lou explains, "There are two main challenges we're always trying to deal with, and they kind of compete with each other. One is just the fundamental technology, trying to get the best therapy for the patients and the best outcomes for a long, healthy life where they're feeling good. With respect to diabetes, it's about keeping your blood sugar under as tight a control as possible within a normal glucose range. So that poses the technical challenges of how to design a control system to do that with all the uncertainties of human physiology and so forth." "But on the other side, the systems we make at Medtronic Diabetes are almost consumer products. In order to get the therapy that they need, the patient often has to contribute to the therapy. They need to indicate when they're eating, for example, and then help the system calculate how much they're eating so that they can dose the insulin properly to manage their meals better. It requires some cooperation with the patients. So, on that side of the challenge is, how do you make the system easy enough to use so that the patient can get the best outcomes possible and do as little work as possible? Because the last thing the patient wants to do is be bothered all the time having to manage their therapy." #MedtronicDiabetes #Diabetes #ContinuousGlucoseMonitor #CGM #InsulinPump  medtronicdiabetes.com Listen to the podcast here

In this episode of Diabetics Doing Things, sponsored by Medtronic, Rob is joined by Monique La Bomme, in an episode recorded live on World Diabetes Day at the Medtronic Diabetes headquarters in California. Monique shares her experience of living with type 1 diabetes and discusses her journey with diabetes alert dogs and diabetes management technology. The conversation also delves into the importance of representation and advocacy in the diabetes community. Topics discussed: 1. Monique's diagnosis story and early days with diabetes 2. Diabetes management, technology, and the use of diabetes alert dogs 3. Representation and advocacy in the diabetes community 4. The impact of diabetic alert dogs on people's lives 5. Balancing diabetes management and social life as an actor and model Here are key takeaways and lessons: - Monique shares her diagnosis story, highlighting the importance of early detection and the role of a lung specialist in her diagnosis. - Her positive experience with diabetes management at a children's hospital and the supportive diabetes community during her early days with diabetes. - The significance of diabetes alert dogs in detecting glucose changes and preventing severe hypoglycemia incidents. - The importance of representation and advocacy in the diabetes community, especially in showcasing diverse experiences and stories. - The impact of diabetic alert dogs on raising awareness and inspiring others to consider using service dogs for diabetes management. References: - Instagram handle: Monique La Bomme - [@moniquenicolee] (https://www.instagram.com/moniquenicolee/) - Medtronic - [Medtronic Diabetes](https://www.medtronicdiabetes.com/) - World Diabetes Day - [International Diabetes Federation](https://www.idf.org/our-activities/world-diabetes-day.html) 00:00  Live from Medtronic HQ: A Type 1 Diabetes Journey on World Diabetes Day 05:09  Navigating Type 1 Diabetes: Community Support and Advanced Technology 09:40  How a Diabetic Alert Dog Changed My Life: Monique's Story 19:33  Breaking Barriers: Advocating for Diversity and Inclusivity in the Diabetes Community

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: a new CGM from Medtronic is approved in Europe, semaglutides for people newly diagnosed type 1 may make a huge difference, a look at Keto diet for kids, Apple teases non-invasive glucose monitoring and Dexcom U is back! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Our top this story this week a new CGM from Medtronic gets approval in Europe. It's called Simplera – an all in one disposable CGM– no fingersticks and no over-tape, which is new for Medtronic. Simplera is integrated with the InPen™ smart insulin pen, which provides real-time, personalized dosing guidance to help simplify diabetes management. Medtronic will begin a phased launch at the European Association for the Study of Diabetes (EASD) 59th Annual Meeting in Hamburg, Germany on Oct. 2-6, 2023. Simplera™ is indicated for ages 2+ and compatible with iOS and Android. Simplera™ is not approved by the FDA and is limited to investigational use in the U.S. Medtronic's automated insulin delivery (AID) system integrated with this next-generation sensor is currently under review for CE Mark and is not commercially available in the U.S. or in Europe. I've reached out to Medtronic – we'll learn more soon. https://news.medtronic.com/2023-09-21-Medtronic-Diabetes-announces-CE-Mark-for-new-Simplera-TM-CGM-with-disposable-all-in-one-design XX A small study and a long way to go here, but a weekly dose of semaglutide, helped seven out of 10 patients newly diagnosed with type 1 diabetes stop taking insulin after three to six months. Semaglutide is the key ingredient in Ozempic.. approved for type 2 and Wegovy, approved for weight loss. It's also thought to tamp down the inflammation that can lead to the destruction of insulin-producing cells. He noted previous research has shown that patients with newly diagnosed type 1 diabetes still have the ability to make some of their own insulin, so the team tested semaglutide in patients within three months of their diagnosis. All ten patients were taking meal time and long acting insulin. After three months, all of them came off meal time insulin, and seven stopped basal insulin. Much more study needed here.. interestingly. Ozempic's maker, Novo Nordisk noted it didn't sponsor this study and isn't pursuing trials of semaglutide for type 1 diabetes itself, https://www.cbsnews.com/philadelphia/news/semaglutide-ozempic-wagovy-type-1-diabetes-insulin-study/ XX a widely used diabetes drug that controls blood sugar can also prevent muscle atrophy and muscular fibrosis—which can help the elderly bounce back faster from injury or illness. Researchers from the University of Utah Health have found that Metformin has surprising applications on a cellular level. Their findings were published in the journal Aging Cell. “We saw two things in our study,” Drummond says. “When participants took Metformin during a bed rest, they had less muscle atrophy. During the recovery period, their muscles also had less fibrosis or excessive collagen. That build-up can make it harder for the muscle to properly function.” https://scitechdaily.com/researchers-discover-surprising-side-effect-of-common-diabetes-drug/ XX Researchers at the Massachusetts Institute of Technology (MIT) say they have created a device for people with type 1 diabetes that may help produce insulin when needed. Their findings were published on September 18 in The Proceeding of the National Academy of Science. The MIT engineers reported that the small implantable device could carry hundreds of thousands of insulin-producing islet cells. Previous devices made for the same purpose failed and stopped producing insulin because they ran out of oxygen needed to create the insulin. To combat this, the scientists created an oxygen factory on the device, allowing it to generate oxygen by splitting water vapor in the body. The researchers said the device could potentially replace insulin injections in people with type 1 diabetes. Dr. Caroline Messer, an endocrinologist at Northwell Lenox Hill Hospital in New York, not involved in the study, explained to Medical News Today: “Currently, islet cell transplant is limited to patients with a history of severe metabolic complications and consistent failure of insulin-based therapies. Long-term success rates are low, and patients require lifelong immunosuppressive therapy. Conceptually, implantable islet cells that do not require immune suppression and create their own source of oxygen is nothing short of brilliant.” MIT researchers said the device kept glucose levels stable for at least one month when implanted into mice. The device has not yet been tested in humans. Researchers hope to create a larger version of the device and test it in people with type 1 diabetes. They expect this device to be about the size of a stick of chewing gum. “We are eager to see this technology translate, but it does take time,” said Dan Anderson, PhD, the study's lead author and a professor of chemistry at MIT. “We hope to see this technology in humans within at most four years.” Although the researchers remained focused on treating diabetes, they indicate this kind of device might be able to be adapted to treat other illnesses that require repeated delivery of therapeutic proteins. “This technology allows for an improvement in the current approach to implantation of units containing cells that produce insulin in response to blood glucose levels without requiring invasive surgery,” said Dr. Eliud Sifonte, an endocrinologist at NYU Langone Medical Associates, who was not involved in the study. “Historically, this approach has been difficult to maintain due to an inability to provide a good oxygen supply to those implanted cells,” Dr. Sifonte told MNT. https://www.medicalnewstoday.com/articles/how-a-new-device-may-help-with-insulin-production-for-type-1-diabetes XX Weight Watchers and Abbott announce their new app for people with diabetes. This is a WW app that integrates the use of a Freestyle Libre. The app helps people with diabetes understand how food and activity impact their glucose levels. WeightWatchers had a team of nutrition and behavioral science experts designed its tailored plan. It aims to help people with type 2 diabetes form helpful habits and meet their health goals. The plan has demonstrated success in helping people with diabetes lose weight and lower their HbA1c, the company said. https://www.massdevice.com/abbott-weightwatchers-unveil-connected-diabetes-app/ XX Italy celiac XX Keto and other low carbohydrate diets have gained popularity for type 2 diabetes in adults, but there are safety concerns for young people, the American Academy of Pediatrics (AAP) cautioned. Restricting carbohydrates in young people at risk for or with diabetes raises concerns for growth deceleration, nutritional deficiencies, poor bone health, nutritional ketosis, and disordered eating behaviors, Tamara Hannon, MD, of Indiana University School of Medicine in Indianapolis, and colleagues on the AAP Committee on Nutrition wrote in a clinical report to guide care. Based on demonstrated risks, low- and very low-carbohydrate diets were not recommended for children and adolescents with type 1 diabetes, "except under close diabetes care team supervision utilizing safety guidelines," the group wrote in Pediatricsopens in a new tab or window. Low-carb (

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, September 22, 2023. Check out the show notes for links to the stories we discuss today at MassDevice.com/podcast. There are more funding raises in the news this week. The first one is from MedTrace, which raised $19 million for its PET-boosting technology. Fast Five hosts Sean Whooley and Danielle Kirsh go over what the funding will go toward and the technology they're developing. ProSomnus is raising $10 million for its CPAP alternative. Find out what the technology is and how optimistic executives are about the future of the technology. Whooley details a regulatory nod for Quantum Surgical's surgical robot in China. Hear about what the robot does, what kind of treatment it offers and what executives think about the regulatory nod. Medtronic Diabetes is having a good year – its Simplera CGM in InPen just won CE mark approval. Whooley and Kirsh discuss what technology and when Medtronic expects to launch the CGM. Hologic and Bayer have announced a partnership to improve mammography imaging. The Fast Five hosts go over the goal of the partnership and how the company plans to meet that goal.

The adults were so weak they had to be carried off the shipwreck onto shore… Today, I lead the diabetes business in Medtronic, a global leader in medical devices. The business is about 2.3 billion, with over 5,000 employees. The story of “the person most likely to rule the planet in the future”20 YEARS IN PERSPECTIVE:I find myself not in the mainstream part of these companies, but having a big impact on the future of those companies.A bit of a nomad - three million miles of travel approximately, 3 continents, 3 children, 3 C-suite roles, 7 cities and 10 addresses.My background is in software, in tech, Microsoft was really formative, doing all things on consumer software and services, the precursor to cloud technologies. I then joined Tyco electronics, and then Honeywell recruited me to be its first Chief Commercial Officer, and then I was promoted to lead the software business.A lot of people say [about Medtronic] “Well, that's very different from some of the industrial companies, as well as the software world” and the funny thing is, the concepts are exactly the same.I used to think working on software apps was really exciting and was going to change the world... Let's say, if you make a game on the iPhone, is that as thrilling as applying your brain power and your energy towards something like the area of diabetes, where you can really help people's lives? It's just not!The biggest challenge… I think actually having kids and having a career is a juggling act for everybody, it always comes back to the question of how much should you work.ON TOPIC: Grit and leadership, rags to riches, the making of a leaderWhen you grow, life gives you certain tools depending on how you get brought up. And when you grow up poor, you get a lot of tools. I had to support my mother, I had to find a way to go to college. So I had to think about how do I make a lot of money while going to school.At 16 I started a business and after about a year I had a hundred students. So I converted the garage, my bedroom and the living room into classrooms and I taught all weekend. I made more money doing this than when I got my first job at McKinsey.It takes courage to confront necessity and accept that bad things happen. Half my life I was living in poverty or close to financial ruin and I missed out on a childhood, but every day I picked myself up...Changing the events that are outside you is not possible, but you can change how you view them, that's possible. So why don't you go and focus on changing what's possible and I think to me those lessons help you deal with adversity.Don't be a poser, actually contribute, figure out what is your unique contribution, be really, really good, build your talent stack and then the opportunity will find you. You can compete by being political, by being self-promotional, but you're not really adding value and I want to go to bed every night knowing I did my best and contributed.It's helpful to have a personal board of directors, it's people that you trust and you've built relationships over time that can pull you back from the brink of your excesses or when you have blind spots.Cultivate relationships, do it because they're your friends or they're people you respect and admire, not because it helps you get ahead.ON TOPIC: Diabetes, medtech, health25% of healthcare is spent on diabetes, that's a lot, in the world.There's about 7 million people that have type 1 and type 2 insulin-dependent, that's a lot of people. If you then go to the broader type 2, you're talking about 200 million people that need some sort of medication. Innovation here is: you're putting something in someone's body.

This long-awaited Medtronic 780G is now FDA approved. It's been out for two years in Europe and has features that are a bit different from other commercially available automated insulin delivery systems in the US, including a target range down to 100. This week you'll hear from Heather Lackey, global medical education director for Medtronic Diabetes who also lives with type 1 and has used the 780G. We talk about what else this system can do – remember this is the one with the 7-day infusion set – and Stacey asks a lot of your questions. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More info here: https://diatribe.org/medtronic-minimed-780g-approved-fda Lackey mentions a study where even with no meal boluses for three months, people stayed mostly in range. Here's that study: The Official Journal of ATTD Advanced Technologies & Treatments for Diabetes Conference Madrid, Spain—February 19–22, 2020.  Diabetes Technology & Therapeutics. Feb 2020.A-1-A-250.http://doi.org/10.1089/dia.2020.2525.abstracts Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Rough Transcription: Stacey Simms  0:00 Diabetes Connections is brought to you by The only Ultra rapid acting inhaled insulin by Omni pod five, the only tubeless pump that integrates with Dexcom G six mi Dexcom G seven powerful simple diabetes management. This is Diabetes Connections with Stacey Simms. This week, the long awaited Medtronic 780 G is now FDA approved. It's been out for two years in Europe and its features that are a bit different from other commercially available systems in the US, including a target range down to 100.   Heather Lackey  0:44 And it's just been proven to do so successfully without really increasing a lot of time below range. You know, what will the next system lead up? Will it be below 100? I don't know. But it's so nice to be waking up with glucose levels that are so much closer to someone without type 1 diabetes with this lower target.   Stacey Simms  1:05 That's Heather Lackey, global medical education director for Medtronic. She also lives with type one, we talk about what else the system can do remember if this is the one with the seven day infusion set, and I ask a lot of your questions. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show. Always so glad to have you here. You know, we aim to educate and inspire about diabetes with a focus on people who use insulin. I'm your host, Stacey Simms, and we are getting some big FDA approvals. Along with the Medtronic 780 G, we got word that beta bionics islet will soon be commercially available. As I am recording this I do have an interview set up with the beta bionics CEO. If all goes to plan that will be our show next week. Real quick, while the original islet dual chambered pump was not what was in front of the FDA, the pump that has been approved has some really interesting features. It's unique in that there are no steps to the programming. When you get your pump, you're not putting in basal rates or insulin sensitivity factors or anything like that. All you do is put your weight in. But that is for next week. You can follow me on social media. We've already shared some information about the islet and I've done many episodes in the past if you want to listen to those to get an idea of what was approved, but this week, we're talking about the Medtronic 780 G, as you likely remember Medtronic at the very first of what we now call a ID systems automated insulin delivery systems with their mini med 670 G and that was approved in 2017. We've been hearing about the 780 G for a long time. It was submitted in 2021. I've talked a lot about the delays in the in the news episodes. It has been approved in Canada since last year. It was approved in Europe in 2020. We're gonna go through lots of features of the pump, but you should also know that the sensor used with this system The Guardian four is approved with no finger sticks for dosing, which to me is one of the most significant changes. My guest to talk about all this is Heather lackey. She has been with Medtronic for more than 19 years. She delivers medical education strategy for insulin pump systems. She trains Medtronic education teams around the world. She lives with type one she was diagnosed at age 16. She was also a consultant on the movie Purple Hearts. She also popped up in a scene in that movie and yes, I asked her about that. Lots to get through. But first Diabetes Connections is brought to you by Afrezza. Afrezza is the only FDA approved mealtime insulin that comes in a powder you inhale through your lungs. So why should you consider this unique alternative to mealtime injections. Afrezzais another option if you want to lower your use of needles or if you're experiencing skin reactions at your injection sites, and it is ultra rapid acting so you can take it right when your food arrives. Even unexpectedly. Find out more see if Afrezza is right for you go to diabetes dash connections.com and click on the Afrezza logo. Afrezza can cause serious side effects including sudden lung problems low potassium and it's not for patients with chronic lung disease such as asthma or COPD or for patients allergic to insulin. Tell your doctor if you ever smoked ever had kidney or liver problems history of lung cancer or if you're pregnant or breastfeeding. Most common side effects are low blood sugar cough and sore throat severe low blood sugar can be fatal. Do not replace long acting insulin with Afrezza, Afrezza is not for us to treat diabetic ketoacidosis please see full prescribing information including box warning medication guide and instructions for use on our frezza.com/safety. Heather, thank you so much for joining me. I have a lot of questions for you about the new system but first welcome. I'm glad to have you here.   Heather Lackey  4:52 Oh thank you Stacey. It's my pleasure to be here and so nice to get to meet you. I listen to your podcast and just excited Good to be a part of this one.   Stacey Simms  5:00 Oh, well, I'm thrilled to have you. And I'm sure you don't mind if I say it has been a long time coming. Lots of people very excited about this improvement. Can we start by just talking about the seven EDG? What makes this different from the Medtronic pumps that have come before?   Heather Lackey  5:16 Yeah, well, the mini med seven add system is different in the fact of course, it let's say what it Phil has right still has automated basal insulin, and that insulin ID based on the sensor glucose values, but this system is set apart because it delivers does auto correction boluses, like every five minutes is needed. So we know that life with type 1 diabetes, as you well know, as a mom, someone with type one and be living with it, we know that life does not go as we expect all the time and as planned. And so many things affect our glucose outside of the three things that we've always tried to juggle for years, right? Food and insulin and exercise. But now that we really kind of identify that there's so many other things that are impacting our glucose, it really brings to light the fact that we don't get it right 100% of the time, when we dose insulin, we adjust food. And so that's where those auto corrections that are coming in real time, every five minutes, if needed, can really help. And what I love about the system is the auto corrections, you don't have to be sky high to get an auto correction. As a matter of fact, you don't even have to be high. before they begin. They're really kind of thinking like a pancreas than as soon as your glucose rises over 120 milligrams, as the basal is working as hard as it can and saying, Hey, I need help, then the auto corrections come into play. And they can start dosing a correction bolus every five minutes if needed.   Stacey Simms  6:59 So what is the difference between the auto basil and that bolus that you're talking about? Because you know, the automated systems that are out right now already adjusted basal every five minutes? What is actually happening when you say oh, and it's also giving a bolus?   Heather Lackey  7:14 Yeah, so the bolus happens every five minutes on top of the date. Right, facie, so let's say, again, the goal for many meds seven ad G, there were kind of two goals in play, right, we wanted to further improve time and range, you know, compared like with the mini med 670 G system without compromising any safety, because we all know we can drive down glucose, right, but you don't want to have a lot of lows. And we wanted to reduce the daily interactions with the system. And those daily interactions, right, the the alerts and the alarms and all of the safety pieces that were were added to mini med seven, add, those have all been now relaxed, and so less than erection and improvement in time and range without sacrificing hypoglycemia. So what's nice about the system is you not only are delivering the auto basil, like you said, right, we have auto basil and other systems that now if the auto basal cannot keep the glucose level in the target range, it predicts that the glucose level is going to go higher than it would like then that's when those auto corrections come. And they don't come once an hour, they come every five minutes. As soon as that since your glucose rises over 120 milligrams per deciliter. If the system says, Hey, I'm working as hard as I can with your basal, and I'm not able to keep your glucose at the target range that we want, right. And we'll talk about targets and here in just a minute, hopefully. But if we can keep your glucose at that target range, then I'm going to ask for some help. And that's where those auto corrections. And those are boluses. Right? boluses that happen every five minutes without the patient having to agree to them, or take any action on their part. They just happen automatically.   Stacey Simms  9:14 Alright, I have a few more questions about that. But I'll get back to that in a couple of minutes. Because I feel like most people will just see the results. And they they may not have too many questions about exactly what's going on there. But I want to get back to that bullets in a minute. But you mentioned range, and the seven EDG has a lower range than Tandem and Omnipod. Five have currently right it's correcting down to 100. Or that's a choice. You can adjust that.   Heather Lackey  9:37 Yeah, there's a couple of things that are different and new about this. And Minimates seven add definitely treats to a target, not a range. But you're right though the target is the lowest target at this moment that's available and so the auto basal target, you can set three settings Three different targets are available to where the person was diabetes , their healthcare provider can can really identify which target is best for them. But the three targets are 100 milligrams per deciliter, 110, and 120. Now 100 comes as kind of the default auto basal target. And that's because we know that this system was all of the copious data that we have. And all of the simulations that were done before this system was even launched, was using that 100 target. And that's what this system is built around to be the best target to you.   Stacey Simms  10:36 We should note that tide pool type pool loop, which was approved by the FDA a few months ago, can correct down to 87. But it is not available in any insulin pump, yet. It's a software program that was approved. So 100 for Medtronic is the lowest that you can actually use right now. But it's interesting, that's 101 10 and 120, where some other systems have, you know, an exercise mode that is a higher range, do you have any insight as to why those were chosen?   Heather Lackey  11:02 Well, those are that close to target to mirror a normal functioning, you know, system a system without diabetes . And the interesting thing is, is the 100 target is very much achievable without sacrificing time below range, right? So we're able to drive with the auto basal target being set at 100. And with having the auto corrections that are even delivering up to every five minutes, this is the system, you know, determined that those were needed. We have the algorithm that built to drive the system to 100. And it's just been proven to do so successfully without really increasing a lot of time below rage. You know, what will the next system lead us? Will it be below 100? I don't know. But it's so nice to be waking up with glucose levels that are so much closer to someone without type 1 diabetes. With this lower target.   Stacey Simms  12:03 Let's talk about the sensor because there are changes here too. Right. Tell me about the sensor that goes along with the 780G? Yeah, well,   Heather Lackey  12:10 the Guardian four sensor is the center that it works with the mini med 780G system. And the Guardian Force center was designed really to reduce the burden as daily finger sticks. That was the whole goal. Let's remove calibration from the system. And let's try to develop a system that doesn't require finger sticks. As we know, sometimes finger sticks still are needed with really with any of the systems and sensors. But the majority of the time when our patients are in the mark guard feature is they are using the SR glucose to bolus off that, you know, there's no real need for a fingerstick glucose. And interestingly enough, most patients bend upwards of you know, 95% or so in that smart guard feature. And so many patients will tell me, I am forgetting my glucose meter at home. And I had one patient that went on a trip, he went out of the country and he said, Look, I totally left insulin and glucose at home because I had kind of forgotten to take my meter bag with me. Wow, learning for sure.   Stacey Simms  13:27 Oh my gosh, yeah, my son goes without a meter quite often. Since you know his we use the Dexcom in the control IQ system from Tandem. But yeah, you don't want to forget your bag entire. That's not good   Heather Lackey  13:38 news. Okay, that's if that's now a burden that is taken off of you. And that's lovely. Yeah, no doubt. No need to be prepared, right?   Stacey Simms  13:47 Yep, absolutely. And I think it's worth pointing out that this is the only automated insulin system in the United States. That is one system, right? It's a glucose monitor infusions that insulin pump. That's all Medtronic and this system has that extended infusion set right so you're talking to sensor you were for seven days, and an infusion set for seven days, right. We'll get right back to my conversation with Heather but vs Diabetes Connections is brought to you by Omni pod. And when you're deciding that a random insulin pump, you got a lot to think about, especially if you've never used a pump before. It really can seem overwhelming. I remember that there are a lot of choices, and you want to make the right decision. And that's why I'm so excited to tell you about Omni pod five. Curious about trying an insulin pump or seeing what life without tubes is all about. Unlike traditional tube pumps, you can try Omni pod without being locked into a four year contract. You might even be eligible for a free trial, go to diabetes dash connections.com and click on the Omnipod logo for full safety risk information and free trial Terms and Conditions. Also visit omnipod.com/diabetes connections. Now back to Heather answering my question about this seven day infusion set   Heather Lackey  15:03 That's exactly right. One kind of new feature of the mini med seven add system is the extended infusion set. And that extended infusion set. It's been launched for a few months in a few different countries. But it comes now with de minimis 780G system, and really allowing people to just kind of have to think about changing a center and changing their infusions that just one day out of the week versus anymore. And so that system, you know, I have so many people that will go have our youth told us for years, you know, that we have to change our infusion set every three days. And why are we able to start to use that system now, and just been using that now for seven days. And the the, it's really simple to explain without getting into a lot of engineering details, but that infusions that is made with this advanced material. And what it does is it helps to reduce the insulin preservative, you know, kind of the loss that we would typically have, it helps to maintain the insulin flow. And it helps to maintain the stability of the unfolding. And so there's such a reduced risk of any kind of blockage or occlusions, with your infusion set whenever you use this new extended infusion set. And I always have to remind patients and people with that need us and their families, make sure you're only using the extended infusion set for seven days, and you're not using your current infusions that are that long, because the materials are different.   Stacey Simms  16:41 Yeah, good point. Can you use any insulin in those extended infusion sets?   Heather Lackey  16:47 So well, in the mini med 780G system, the insolence that are approved and on label are human log and Nova logs. So both of those are available to us with that set.   Stacey Simms  16:59 So no, Lusia if I ask, just checking, those are not approved at this time. Got it? Got it. I had a listener ask if the duration of insulin is adjustable, you know, is that a setting that people can kind of go in and tinker with?   Heather Lackey  17:13 Yeah, so active insulin kind of talks about the or is our duration and insulin kind of tuning knob that is in the programmable settings on the mini med 780G pump, the active insulin Time is of the two settings that are critical is one of the two, right the first setting is the auto label target, you know, looking at that 100 glucose target for most people with diabetes, but then also setting the active insulin time to two hours. And a lot of people will say, Look, I have never had active insulin or insulin on board. I've never thought that human log or Nova log was out of my body in just a couple of hours. And so it's interesting that Medtronic is recommending a two hour active insulin time. Why is that? And the real answer is this is what the algorithm was designed around, right, it's fine to have the ability to, you know, the algorithm is asking the patient, if you set the active insulin time to two hours, then that gives me the ability to calculate insulin, if I think it's needed, right, that doesn't always mean that you're just gonna get insulin stacked on top of, you know, each other dose on top of a dose every two hours. It just means that gives the algorithm the ability to give correction sooner. And whenever you're giving those auto correction. as frequently as every five minutes, it makes sense to be able to just kind of give the algorithm the freedom to make the decision if it's needed. And anytime I have someone that really wants to debate this, and understand how the algorithm works, I just always have to say, let's just look at the data. And you know, we're not stalking we're not having hypoglycemia in the 10s of 1000s of patients that we have data on.   Stacey Simms  19:06 Yeah, it's actually I wish I had a diabetes educator. Maybe this will be for another episode. You are obviously a diabetes educator. But it'd be fun to have somebody else from a different pump company because other pump companies will say no, no, no, exactly. As you're saying like you're stacking insulin. We set it this way for a reason. It's not adjustable for a reason. Is this two hour duration. A different setting from previous Medtronic pumps forgive me? I'm not as familiar with them.   Heather Lackey  19:29 You don't know. That's a great question. They see it the same accident one time. Honestly that has been a part of the bolus calculator settings, the bolus wizard and now the smartcard bolus feature that even since the paradigm days, right, when the bolus calculator was first presented, we're now looking at decades ago with the active insulin time. So it's the same setting we've had, but now it's kind of viewed in a different way than Then it has been in the past, right? In the past, it was very traditional, like you're saying and, and kind of how patients will think of it with, you know, whenever I'm in conversation with them, they're like, How can this be. And the simple fact is, with setting the accidents one time, as low as two hours, which is what we see the best control, the best time and range and the lowest time below range, right? So the fueler lows is actually set at two hours. And what that does is it just is a tuning algorithm knob. And it says, Hey, algorithm I'm going to allow you to give, if you determine that it's necessary, meet Insulet. And because you're looking at my rate of change, you're looking at how much insulin is on board, you know, how many grams of carbohydrate that I've entered, it takes all of this information into account and decide if action should be taken. And what lovely is the patient, the person with diabetes that mom, dad, the family, they don't have to make any of those decision, the system is doing it for them.   Stacey Simms  21:05 It should have probably started with this question. But what does the algorithm use as a starting base? You know, we're used to traditional insulin pumps where you sit with your educator or your doctor and you say, Here's my basal rate, here's my sensitivity factor or correction factor, or, as we're talking about here, duration, there is a pump in front of the FDA right now that just uses body weight. What is the 780? G use?   Heather Lackey  21:26 Yeah, that's a great question as well, algorithm really start with total daily dose of insulin, kind of as it is its starting point, right, the calculation. And that's why whenever you are new on the mini meds 780G system, people have to stay in manual mode. So the kind of the non auto basal in auto correction kind of piece of it. So they stay in manual mode for 224 hour days, right. So it's two days in manual mode. And then there's enough data as a starting point for this system to be able to, to say, Okay, this is a safe basal amount for you to begin with. In addition, if there's sensor glucose tracings, in that 48 hours of kind of that warmup period, to the smart guard feature, then those fasting sensor glucose level pump is looking to see like, how much insulin Do you require, whenever you're not announcing meals and, and so it see, okay, this is your center, glucose is in a fasting state. Now, how much auto Basil is being delivered. And that is kind of the two main pieces of information of how the system decides how much auto basil to begin with, and to deliver,   Stacey Simms  22:49 got it, can the user switch back to manual mode,   Heather Lackey  22:53 yet, they can, at any time, they can stop the smart guard feature, we know that the data is so overwhelmingly heavy weights heavy on the smart guard side. So we definitely see a major difference in time and range being improved. Whenever people are in this barcard feature versus in manual mode, right? They're always encouraged to say and   Stacey Simms  23:16 got it but the system doesn't like. And I hesitate to say it this way. But you'll know exactly what I mean, the system isn't kicking people out as much as one of the very early automated systems for Medtronic, right? That was a big complaint with the 670 was I got kicked out of auto mode.   Heather Lackey  23:30 That was a complaint. And we know that whenever the mini med six, seven ad system, the first hybrid closed loop system of its time was a pretty conservative algorithm, right? Because it was first of its kind, Medtronic really had to build on a number of safety precautions. And in many cases that led to those unwanted alerts and alarms and interactions with the pump to keep the system kind of in that auto mode, smart guard auto mode feature. And so with this, we the exits on mini med 780 G system. I mean, they're just not happening, right. And again, though, the number one of two goals of this system was to reduce the daily interactions with the system. So we can't have beats and alerts and alarms. And hey, you have to enter a BG all the time in order to stay in to the automation mode. This is a big difference that people especially those that have been on previous hybrid closed loop systems of all kinds, they're like this is really a pretty big change right? exits at night, exit in the daytime alerts at night. Those are some of the things that are really different from a user lens. Whenever I hear anyone asked my husband, you know, like what kind of from your standpoint In a view, what's the biggest change with you seeing your wife were the minimis 780G system for a while. And he just says, look, it just doesn't wake us up at night. And he just seems to be a little bit more pleased. A lot of surveys that have been conducted all throughout, you know, the countries where people are using and wearing many hats, 7080 G system, you know, it's like 94 95% of people are saying that they're satisfied with the impact on the their quality of life, they're happier with the quality sleep, that's one that's pretty high, ranked and desired by many. So for us to get a good night's rest and to feel confident to go to bed, lay our head down, not have lows or highs not have alerts and alarms. That's the system that we need. And that that's what people are enjoying.   Stacey Simms  25:54 One more question about manual mode, a listener had asked me is manual mode usable during the auto mode? In other words, if somebody really feels like they need to do an additional bolus, can they do it?   Heather Lackey  26:05 It can be done, but I would kind of ask why do they feel like it needs to be done? Right? Why would you need to go out to manual mode if you need to give an additional bolus. So carbs can be entered at any time that those are consumed? Right, we definitely want to announce our mills. And at any time in the smartguard feature, a patient can always look to see if if they what we kind of say a user initiated correction dose is needed. So you don't you know, I don't ever want people to feel like once I'm in the smart guard feature, guy can't take action. If I see glucose, where I don't want it to be or if I've eaten something that I didn't tell it, you know, go ahead and deliverable list, at least check to see if a bolus should be given. And maybe some of the feedback that patients had on mini med 670 G system where they felt like they had to enter in perhaps kind of ghost carbs or fake carbs when they weren't actually eating them to kind of trick the algorithm to giving more insulin, I think you'll find with now that control that we have able to control on this system like that active insulin times and the auto basal. I don't see that people at all are having to what we say automate the automation? Well,   Stacey Simms  27:27 yeah, we let me ask you a follow up on that. Because I don't know anybody who uses an AI D system who just puts in meal boluses and says, Great, I'm always in the range I want to be are you saying that's what's happening with the 780?   Heather Lackey  27:39 Well, I'm saying that anytime that you eat in any of the AIP systems, right, you can you can enter those grams of carbohydrate. But because many meds 780G system gives the autocorrection doses starting at anytime, and glucose is over 120 systems. If the auto basal can't handle that glucose response, then they're gonna get it. So because you start you intervene the system intervene early and intervene often, there's less of the need to take matters in your own hand. Right. So it's a different mindset. Really it?   Stacey Simms  28:18 Yeah, no, it's absolutely it sounds great. Well, we'll see. When you said meal announcements, to be clear, you're talking about carb counting and putting in the numbers of carbs you're eating, you're You're not just saying I am eating?   Heather Lackey  28:31 You're saying I Yes. You're you're entering grams of carbohydrate. Thank you for clarifying going   Stacey Simms  28:36 no, I'm just you know, I know it's coming. It's amazing to see how these things are changing. I just want to be clear as we go. Yeah. Well,   Heather Lackey  28:42 you know, that's kind of a segue Stacey to a lot of the different thoughts on do people have to now with autocorrection? Do people have to be so precise on the grams of carbohydrate that they're entering into those bits? Okay. Well,   Stacey Simms  28:59 let me give you Yeah, let me let's segue into that. Let me give you the best case use that I can make in my house or something like this. I have an 18 year old, he's a great kid. He's very responsible with diabetes. He is terrible about bowling before he eats. It's just it's just not happening. And so we have a lot of, you know, excursions that perhaps don't necessarily need to be happening. I would be thrilled at a more aggressive post meal bolused system. So talk me through what happens to scenarios for you. Somebody has an AD of just throw 85 carbs out there because this happened recently. So somebody has an 85 carb dinner, they bolus five minutes after they finish it. Or somebody has an 85 carb dinner and completely forgets to bolus how does the system handle those things? Oh, yeah.   Heather Lackey  29:45 Well, I'd love to show you my report. Because not only does it happen with an 18 year old, it happens with me more than I would like oh my goodness. I plan for 33 years. How am I forgetting to push the button,   Stacey Simms  30:01 I love it, you're human, you're human. I'm totally   Heather Lackey  30:04 human. So the 85 gram carb dinner, and they bill it five minutes later, right? We know that if you are not giving insulin before the meal, right, you're gonna have food most likely showing up to the party before the insulin arrives, right, so you're gonna have food, their glucose is gonna rise because of the food digest. And then here comes insulin. In that case, we would say, Look, if then, you know, if you're really bolusing, after the meal, you probably are going to need to reduce your meal Bolin, than we have some exact parameters for healthcare providers to kind of discuss with their patients. But you know, on average, it's like, look, probably just dose for, you know, maybe that path in your case, maybe it's not, because as you know, as those is that sensor, glucose starts to rise, the auto basal start to increase, it gets to the maximum, let's say, and then here comes the auto correction. And then you've got insulin, you know, from the bolus still showing up to the party at that point. So what's so great about this system is it knows like, okay, auto Basil is increasing, then there's some, you know, potential auto corrections, as soon as the bullet is given, the system goes, Okay, let's just, let's back off, right, let's see, what's gonna happen with the system before we really just push the pedal to the metal and start giving more correction. Right? So everything is done with the total safety in mind, right, which is something that's so great. Now for the 85 grams of carbohydrate, and they don't bolus at all, well, then that's really what are the auto corrections and the auto basil can shine, that's really where you're going to see sensor glucose is rising. And am I going to say they're never going to go high with an 85 gram carbon bill, I would say that wouldn't be, you know, really unlikely, depending on what what the nutrients are in that food, I would think it was going to be unlikely. And so glucose is going to rise, the system is going to to handle it as as well as it can. But what I can see time and time again, with when mills are skipped, that patients don't go as high and they don't say as high as long. But we have a study that actually support that patient who did zero pole was seeing for a period of time. So this is every single meal for this length of time. And I'd have to look at the report to know exactly the days, but their time and range was just right under that 70% of time and rain. Yeah. And so that's not at all what we are recommending, because we know that if you bolus and you're using the recommended settings, it doesn't matter if you're eight year old, or if you are a 18 year old, or if you're a 58 year old or if you're a 78 year old, we know that for everyone, you can have an upward time and range of 80% plus, right. So we know it's better. And we absolutely want to provide the charge that we should be announcing mil but it's so nice, whenever the occasional I forgot to bolus to you know,   Stacey Simms  33:29 sort of occasional   Unknown Speaker  33:32 got your back for some more than   Stacey Simms  33:36 excellent. I did get this question about the bolusing system, how much of a correction is given? Because on some of these other systems, it's a partial correction. I don't know if you can share that, you know, it's it may be part of the algorithm that you can't share. And then also, how does the system differentiate? Or does it between a missed meal and a random high? You know, a high that may come for another reason?   Heather Lackey  33:57 Yeah. Thank you good questions. Okay. So for the repeat the first one, if you don't mind, sure   Stacey Simms  34:03 how much of a correction is given, you know, like on the T slim, I think I may not be correct here, but it's something like, you know, once an hour can give 60% of the program to bolus. So is that something that the Medtronic keep some good and maybe proprietary? Well,   Heather Lackey  34:16 I can tell you this is the difference with the mini med 780G system is it gives a full correction, you know, if needed every five minutes and every correction bolus, right? It's like if you were giving a correction yourself with a pump, you're going to enter your glucose. The system does the same. It says look, this is where the glucose is. This is where I want it to be. And it's targeting 120 Whenever it's giving a correction dose of insulin, right. That's why after 120 it can start to deliver a correction dose and it looks at the difference and it sees how much insulin is going to be needed. And then it also applies other metrics as well like how much insulin is circulating in the body and And then it determine the safe amount that is going to be needed every five minutes. Got it?   Stacey Simms  35:06 Got it. Okay, great. And then the other question is about does the system differentiate between, you know, missing a meal or a high for another reason? And I could think of highs, you know, and teenagers for, you know, hormones or exercise, things like that, does the system differentiate? And I guess the follow up is, does it need to, or is a high, just a high,   Heather Lackey  35:24 you know, really high is the high and and that's what's so great about the the system anytime there is a rising rate of change, and you know, parameters are met, that the pump says, Wait a second, this is a rising rate. Oftentimes, it's a meal that's missed right? To meet the parameters. When the system sees that this is Matt, what it does is it allows a correction dose to be delivered even a little bit more aggressively. Right. So you know, it does have a mill detection module built in. It has mill detection technology built in, but it doesn't so much say, Oh, this is your sensor, glucose is rising now because of the meal. So I'm going to act this way. Versus your since your glucose is rising, because you have hormone releasing in the middle of the night and you're sleeping, right. Either way, this system is looking at the sensor glucose response. And if it's corrections need to be delivered in a more aggressive manner, or larger corrections need to be delivered either way, then the system is able to do that. You know,   Stacey Simms  36:40 we've mentioned several times that you live with type 1 diabetes. I mean, I know I can talk to you about the pump for probably another two hours. And I hope you'll come back on and we can talk more about it. But I want to ask you about your your journey. You were diagnosed as a teenager, what did you use what was the first diabetes technology, I assume it was a blood sugar meter. coming right back to Heather in just a second. But first Diabetes Connections is brought to you by Dexcom. And Benny has been using the Dexcom CGM for almost 10 years now, that first insertion was in 2013, just before he turned nine. I mean, it was great. Then if you've done finger sticks for a while you know how amazing it is to go from that to continuous glucose monitoring. But it is even better. Now. The Dexcom CGM systems just keep improving, continuing to get more and more accurate with no finger sticks or scanning required. The easy push button insertion has made it easy for Benny to do it himself. He has done every one since we switched to the GS six in 2018, which is really great for his independence back then, as a younger teen. Of course, we still love the alerts and alarms, and that we can set them how we want if your glucose alerts and readings for the G six do not match symptoms or expectations. Use a blood glucose meter to make diabetes treatment decisions. To learn more, go to diabetes connections.com and click on the Dexcom logo. Now back to Heather talking about what things were like she was diagnosed at age 16.   Heather Lackey  38:10 Yeah, you know, I was diagnosed in 1990. And of course, I had a meter. The old lancing device that I had was the one that you lay on the table and it's spring loaded and it like warm around like a hammerhead, and it would poke your finger. Right. So that was my first one. And you know, I was just on conventional insulin therapy, right, at least had disposable syringes. I wasn't sharpening a needle or have a glass of orange or anything like that. And you know, for me, Stacy, my parents were so great. My dad worked internationally. And they were just constantly talking to people like what, there's got to be something that right because I was doing everything I could, I mean, I really tried hard. And I have for, you know, three decades, tried hard to really kind of manage things. And they said, you know, there's got to be something better. And that was right at the end was actually before the end of the DCCT trial, when my parents were told, Hey, there's, we've got to get her on something better. We're starting to notice that these multiple daily injections are going to be a lot better. So went to went and started multiple daily injections. And at that point, this was in 1992. At that point, they they the healthcare team said you ought to consider a tump you're you're young your parents have insurance. You guys are certainly kind of wanting to have the best control you should consider a pump and Stacy for cash for seven years. The first seven years after I was diagnosed I did not want an insulin pump to save my life. I wouldn't even think about it until someone said hey, I had gained some weight in college, as many females and male do and I was trying to lose weight exercising to on the elliptical and or the treadmill, either one. And every time I would exercise, I would go low. And every time I would go low, I would have to have juice and peanut butter crackers, or whatever the case was, and I was having more calories than I had exercised off, you know, you can see the counter of your calories that you're burning. And I'm like, This is ridiculous, I'm going to continue to go low, and not be able to trim down my weight some, and I didn't have the right tools. And so that's the reason I started on a pump and then have been on a pump. For the last, I don't know, 2026 27 years, maybe when you   Stacey Simms  40:37 used to do a lot of patient training on insulin pumps, I know you still do some now, I'm even in your role here. What are their biggest concerns? You know, there's a lot of mechanical learning if you've never used an insulin pump before. But there's also as you mentioned, there's a reluctance sometimes. Can you share a little bit about what patients tell you?   Heather Lackey  40:54 I think the unknown is the biggest thing for patients, right? They don't know if it's surgical, they don't know if it how this goes in how you disconnect, how you're going to get live. The five emphases as I call it, you know, how do you sleep? How do you shower? How do you swim? How do you go in, you know, with exercise and do sports, what happens with intimacy and things like that, you know, those are unknown if you haven't met with a an educator or you haven't had a friend or even a health care provider that's kind of talked to you through that. So I think once people understand how insulin pumps and continuous glucose sensors kind of work inside of our life, and really how easy they are. The trainings are so much more simplified today, because the therapy is so much easier, right? And so I think once they start to see they're starting to put the pieces together, like the technology is working in the background, I don't have to work as hard. Here's the the, you know, two or three things that I have to do change my infusion set once a week, change the sensor once a week, and then I have to enter some grams of carbohydrate, however those grams of carbohydrate are calculated, then they start to understand this is not as big of a deal.   Stacey Simms  42:09 All right, I have to go back. You said the five S's and then I kind of heard you editing as you went, you can say six on this podcast. But what were the other ones we had sleep swim.   Heather Lackey  42:18 So fleet that were when boarding and zek?   Stacey Simms  42:22 That's great. I love that list. That's a great list. All right, before I let you go, I can't let you leave without talking about Purple Hearts, this Netflix movie that you were a consultant on, right? Tell me a little bit about what happened there. This is a character that has type one. And she marries a marine to get benefits health benefits. And it's a very romantic story. How did you come to be a consultant on that? And what was it like? Well, what was so interesting   Heather Lackey  42:46 about this, I mean, it was I mean, what a one and a life champ or V I mean, it was really great. The director, or producer, I think it was the director, she had reached out to Medtronic, specifically, because she was, you know, obviously going to be doing this movie, and the hurt. So her team had reached out to Medtronic. And she really wanted to one US product in the movie. But I guess her colleagues and friends and and others that he had talked to whenever she mentioned that this character was going to have type 1 diabetes. They were all like, Yeah, well, we, you know, we've learned that Medtronic pump for, you know, years and years. And so that's why she reached out, right, so reached out to our communications team and our marketing team. And those teams were so great to say, hey, look, they're going to be using a pump and sensor on the set, they might need to have some help. Just making sure that everything is used correctly. And you know, you're always in film, in movies, etc. Whenever I see things being used in an incorrect way. So yeah, so anyway, I was able to go out on the set. And then, you know, one thing just kind of led to another and they were like, well, you know, we're gonna need someone to train. You know, Sophia Carson is the actress. I mean, like, what an amazing thing to be able to beat her and all the other dudes amazing talent on that, that and they were like, Why don't you I mean that you do this? So why don't you just do this in the movie. And I was so happy that that tiny little piece was not cut it, it was such an important thing for my friends and family to be able to see so. And it really does kind of make people with type one I've heard over and over it was kind of cool for the film to kind of walk through people without type 1 diabetes. Like there's a trainee, you know, like, we have to get to understand how to use this equipment. And it's kind of the big day whenever you go on an insulin pump. The coolest thing about the scene that I was in with Sophia Carson, whenever she we finished the scene and she got on the system and we had everything is moving and working at and it was it was there. She was like, Heather, this is amazing that people go through this. And then she was like, gonna give you a hug like this is like I feel empowered having this system on me whenever I'm playing a character that has type 1 diabetes, so it was very organic and natural. And that wasn't anywhere in the script, you know. So it was just a true testament to how powerful technology is and people with diabetes. Five,   Stacey Simms  45:31 is there going to be a second one?   Heather Lackey  45:32 I have pushed. I have said, I hope that there is everybody wants to know what happened to those two characters. I don't know about it, but I would I would love to see a second movie as well.   Stacey Simms  45:45 That'd be great. Well, we will leave it there. Thank you so much for sharing so much of your time with me. I would love to have you back on to talk more about this system. We still have a lot of questions. I'm sure we just scratched the surface. But I really appreciate your time. Thanks so much for sharing so much information.   Unknown Speaker  45:59 Thank you Stacey. Have a great day.   Stacey Simms  46:05 You're listening to Diabetes Connections with Stacey Simms. Lutz where information with diabetes dash connections.com. I know we didn't get to all of your questions. I will definitely talk to the folks from Medtronic. Again, I thought Heather was really terrific. And she laid everything out. I loved her five S's. But you should also know that the 780 G she mentioned this. It's currently approved for users seven years old and above with type one, they have started taking pre orders that happened in the middle of May, and they will be shipping later this summer. throughout the US. If you have a 770 G, you will be eligible for a free upgrade through remote software. If you want to be notified more, you can go there's a link in the show notes and get their upgrade notification newsletter. So just go to diabetes connections.com Click on this episode's homepage. It'll give you all the information that you need. I'm taking a deep breath because as I have been telling you, my May was bananas. It was wonderful. It was busy and all the best ways. But I mean, I went to Ireland at the beginning of the month. Then I went to New Orleans for my daughter's graduation. Then we had a giant family reunion at my house. So hopefully as you're hearing this, nothing that busy has popped up for the month of June. What I do have on the calendar is the ADA Scientific Sessions conference toward the end of this month. I have never been to this. I've always tried to make it but it's never worked out. So I have immediate pass. I have my microphones packed Well, not yet, really. But I am going to be going and talking to all of these companies. I'll be putting stuff in the Facebook group. So please join Diabetes Connections, the group or sign up for our newsletter. And you can do that at diabetes dash connections.com Because I'm gonna be asking what you want here, who do you want me to talk to what questions you want me to ask. I'm going to try to do a whole bunch of interviews while I'm there and set up a whole bunch more. You can always email me Stacey at diabetes connections.com. I'm super excited about going to this event and really hoping to bring your questions to more of these folks. As I mentioned at the beginning of the show, I am scheduled to talk to beta bionics about the eyelet so that should be next week's episode. And of course we have in the news this Friday to fill you in if there are any more FDA approvals a there's more stuff in front of them. This has been a really interesting year so far, and we're not halfway through. Thank you to my editor John Buchanan, audio editing solutions. Thank you so much for listening. I'm Stacey Simms. I'll see you back here soon until the end. Be kind to yourself.  

Medtronic, as a leading medical device company, plays a significant role in the industry, and its stock performance is closely watched by investors and industry experts. The recent dip in Medtronic's stock can be attributed to the company's growth projections falling short of market expectations. Fast Five hosts Sean Whooley and Danielle Kirsh outline the company's performance in the last quarter and what it anticipates for the future. HeartBeam's win of an AI-related patent for its handheld vector ECG (electrocardiogram) device highlights the company's commitment to innovation and technological advancements in cardiac care. Whooley explains how the technology works and what's ahead for HeartBeam. The FDA's approval of Zoll therapy for sleep apnea patients undergoing MRI scans is a significant development in the field of sleep medicine. The approval of Zoll therapy specifically for patients requiring MRI scans ensures that individuals with sleep apnea can undergo necessary imaging procedures without disrupting their treatment. The Fast Five hosts discuss how the technology works and the impact this will have on patients. Boston Scientific's decision not to acquire a majority stake in M.I. Tech signals a strategic move for the company and highlights the complexities involved in business collaborations and acquisitions. Whooley provides the details of the original transaction terms and what caused the company to bow out, along with commentary from the Federal Trade Commission. Medtronic's planned acquisition of EOFlow, a wearable insulin patch maker, for a substantial sum of $738 million highlights the growing interest in innovative solutions for diabetes management. This acquisition demonstrates Medtronic's strategic focus on expanding its portfolio of diabetes care products and its commitment to providing patients with more convenient and personalized treatment options. Kirsh and Whooley discuss the purchase and how successful Medtronic Diabetes has been recently.  Check out the show notes at MassDevice.com/podcast.

In this episode, hosts sit down with Robert Vigersky, MD, chief medical officer of Medtronic Diabetes, for a discussion around the MiniMed 780G, including use, exclusive features, and how patients can obtain the new system.

Find out more about Yoni and the amazing things he is doing: https://www.linkedin.com/in/yonkoz/ ✈️✈️In this episode of the Margins Business Digital Entrepreneur podcast, we had the pleasure of interviewing a true innovator and entrepreneur, the Co-Founder & CEO of Escala, MultiplyMii, and South Col, among other successful ventures. With a track record of scaling businesses and building top talent teams in the eCommerce and Amazon industry, our guest shares valuable insights on how to succeed in today's global market. ✈️Escala & MultiplyMii are game-changers, providing end-to-end executive search & HR functions and management consulting services that focus on process improvement to build efficiencies at scale for the top eCommerce and Amazon talent in the Philippines. By building our teams in the Philippines, we're able to offer the best global talent at a fraction of the cost of Western world prices. ✈️Prior to founding MultiplyMii, South Col & Escala, our guest scaled an Amazon business from 2M to 5M in 12 months, utilizing their experience in digital agency land to build a fluid process and a team of incredibly talented individuals in the Philippines that would have cost 6 - 7 times more for less capable first-world counterparts. With over 10 years of experience in digital marketing and creative advertising in Australia, Israel, and Los Angeles, they've worked with major brands such as Mercedes-Benz, MasterCard, Sony, Medtronic Diabetes, Mondelēz International, and eight-figure eCommerce brands. ✈️At MultiplyMii & Escala, we're not just in it for the profits; we're a social mission-driven organization that empowers our amazing Filipino team by providing a stable and comfortable work environment for them to thrive. We pride ourselves on paying the best wages and benefits to firmly support our partners (both team and client alike). ✈️Our guest is a firm believer that in life, it must always be win/win, and that there's no partnership when someone is getting 'the better end of the bargain.' If you're interested in learning more about how to succeed in eCommerce and Amazon businesses, be sure to tune in to this episode. #MarginsBusiness #Entrepreneurship #eCommerce #Amazon #Philippines #TalentAcquisition #ManagementConsulting #DigitalMarketing #WinWin #Partnerships #ScalingBusinesses #SocialMission #Empowerment ⚡PODCAST INFO: - Spotify: https://open.spotify.com/show/6yCxWqyExoUugy6yICstyU⚡ - RSS: https://anchor.fm/s/efa56a0/podcast/rss SOCIAL: - WEBSITE: https://marginbusiness.com - INSTAGRAM: https://www.instagram.com/marginbusiness/ - FACEBOOK: https://www.facebook.com/marginthecompany - TWITTER: https://twitter.com/InfoMbcom - Medium: https://marginbusiness.medium.com/ - PINTEREST: https://www.pinterest.com/marginthecompany/ - LINKED IN: https://www.linkedin.com/company/marginbusiness/ - LINKED IN: https://www.linkedin.com/company/the-best-translations - LINKED IN: https://www.linkedin.com/company/bestphotosamz ⚡Brand new HELIUM 10 offers the best Amazon tools to improve your sales Brand New Offer Below 20% OFF 6 MONTHS ($120 VALUE)⚡ ⚡https://crushtrk.com/?a=1806&c=188&p=r&s4=MARGINBUS20&s5=PURL-005977⚡⚡Don't forget to like, share and subscribe for more of this mind-blowing content and hit that bell icon to never miss a video.⚡

Hiring is one of the biggest challenges when it comes to scaling your business. Without talented people in place, hiring efficiently and finding top-notch talent proves challenging--to say nothing about what happens if they don't get along or have different skill sets that prevent them from working well together!  In this episode we'll be talking with Yoni Kozminksi who can help you avoid these pitfalls by sharing his insight, processes and systems to find the right talent for your business.  ABOUT YONI Yoni Kozminski is an entrepreneur and business consultant with over two decades of experience in scaling businesses. Over the years, he has helped develop digital strategies for some of the world's biggest brands, including Mercedez-Benz, Mastercard, Sony, Medtronic Diabetes, Mondelez International, and more. His experiences eventually led to the creation of Escala and MultiplyMii - two companies that help businesses achieve massive growth.  Besides being an awesome entrepreneur, Yoni is also a seasoned podcaster! His 'Successful Scales' Podcast is centred on questions related to growing, selling, acquiring, and scaling a business and what comes with it. If you're looking to take your business to the next level - you don't want to miss out on his wisdom! Here's a summary of the great stuff that we cover in this show: To build a business that stands the test of time, you have to invest in your culture and delegate accountability to your people instead of tasks. One of the number one mistakes that people make when building processes is they take a bottom-up approach, but it's looking on the high level and understanding how everything integrates inside of your business that will help you succeed in building out an effective process. As soon as you get to the level where you start to feel stretched, that's when you should start enacting some of these processes, but you want to actually get to them sooner rather than later. Starting with a Word doc or an Excel spreadsheet and simply defining everything might be a great place to start. You want to build more time in your day so that you can focus on the things that are going to have the most impact in your business and in your life. When you look to build systems in your business, you must first consider where you are investing your time and then understand where you can give ownership and accountability. The perfect system is one that brings perfect harmony between people, process, and technology. Enjoying listening to our conversation about scaling your business with talent :-)For complete show notes, transcript and links to our guest, check out our website: https://my.captivate.fm/www.ecommerce-podcast.com (www.ecommerce-podcast.com).

It's "In the News..." a look at the top diabetes stories and headlines of the past seven days. This week: new information about COVID and type 1 in kids, a new way to look for diabetes before symptoms appear, Medtronic may be ready to ship their 7-day infusion set, approved more than a year ago, and more. Thanks to our sponsor, T1D Exchange: www.t1dexchange.org/Stacey Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX A pair of studies released within days of one another have produced conflicting reports related to the apparent increase in type 1 diabetes diagnoses following a COVID-19 infection in younger patients. one of the studies suggests a COVID-19 infection was associated with up to a 72% increase in new diagnoses of type 1 diabetes, the second, suggests while overall rates of diagnoses may be elevated, COVID-19 may not be the cause of increased prevalence. The second group says we need to consider what has happened regarding the spread of viruses such as enteroviruses during the pandemic, and whether there are any other environmental factors, such as sunlight exposure and vitamin D levels, that might have altered during lockdown that might also be relevant.” The group whose findings suggest covid is the link are asking families with any family history of type 1 to watch for symptoms in the year following a child's Covid diagnosis. Both groups are pushing for more study, https://www.endocrinologynetwork.com/view/studies-debate-link-between-covid-19-and-increased-type-1-diabetes-diagnoses XX Insulin pricing legislation might get another look this year.. Sens. Jeanne Shaheen, D-N.H., and Susan Collins, R-Maine, are working to update a draft bill that would cap consumer copays for insulin in the commercial market and incentivize drugmakers to lower list prices. One of the bill's provisions capping Medicare copays at $35 a month was enacted as part of the Democrats' budget bill in August. The bill would extend the $35 Medicare copay cap to the commercial market. It would also ban health plans from requiring doctors' approval before prescribing a drug and prohibit manufacturer rebates when drugmakers freeze their list prices at 2021 Medicare net rates. Senate Majority Leader Charles E. Schumer has repeatedly voiced plans to bring the bill to the floor but the timeline keeps slipping. It's not expected this would make it in front of lawmakers again until after the midterms. https://rollcall.com/2022/09/28/lawmakers-eye-lame-duck-for-unfinished-business-on-insulin/ XX The Medtronic Extended infusion set (EIS) is the newest insulin pump infusion set from Medtronic and the first and only set that can be worn for twice the wear time! With the Extended infusion set and reservoir, patients can keep the infusion sites they prefer working longer while also benefiting from the easy insertion process currently available with the MiniMedTM MioTM Advance infusion set (which also means training is a breeze). The Medtronic Extended Insuion set worn on the arm. Components of the Medtronic Extended infusion set We know you're wondering how does this work? The EIS introduces innovative technology that allows for longer wear by mitigating the insulin degradation and preservative loss seen in 2–3-day infusion sets. Specifically, it is designed with tubing that features advanced materials to help reduce insulin preservative loss and maintain insulin flow and stability. It also has a new tubing connector that improves the physical and chemical stability of insulin by filtering out insulin fibrils. Fibrils are strands of destabilized insulin that clump together and can contribute to poor glycemia due to infusion set occlusion and immune response at the infusion site.1 Lastly, the EIS has an improved adhesive patch that extends wear-time and provides comfort, keeping the infusion set in place for up to 7 days. All these elements help to further reduce the burden on the patient. What if a patient uses more than 300 units of U-100 insulin in a 7-day period? No problem. Patients with increased insulin needs will also be able to benefit from using the Extended infusion set by simply changing their reservoir mid-way through their use of the set. To support these patients, innovative and simple training resources will be made available. Stay tuned for more details regarding the Medtronic Extended infusion set and reservoir product launch later this year! In the meantime, if you have any questions, please contact your local Medtronic Diabetes representative. https://www.medtronic.com/us-en/healthcare-professionals/therapies-procedures/diabetes/education/diabetes-digest/extended-infusion-set-and-reservoir.html?fbclid=IwAR0HntZBo0NuYSH_hqPAVHQTJrvkZdXK3-pSooS5UOqPuK_S3-AM8cheYqk XX A possible new way to test for type 1 diabetes way before symptoms.. very early here but new research is trying to pinpoint the start of the auto-immune process. These researchers at Boston University say "Previous studies have focused on the triggers, genes and proteins that differentiate individuals with T1D from those without diabetes with a focus on the b-cell (b-cells create antibodies) as a target of immune destruction and blood glucose as the main abnormality Their focus is on metabolic communication as an early instigator with the b-cell as an active participant together with the immune cells," explains corresponding author Barbara Corkey, Ph.D., professor emeritus of medicine and biochemistry at BUSM. According to Corkey, her research led her to generate the testable hypothesis that the induction of autoimmunity is a consequence of one or more major inflammatory events in susceptible individuals. It's al ot more complicated than that.. I'll ink up the research published in the journal Diabetes. https://medicalxpress.com/news/2022-09-hypothesis-autoimmunity-patients-diabetes.html XX Hysterectomy is the second most common surgery for women in the United States. About 600,000 hysterectomies — the surgical removal of part or all of a woman's uterusTrusted Source — are performed in the U.S. each year. Previous research has linked hysterectomies to an increased risk of cardiovascular diseaseTrusted Source, incident hypertension, and thyroid cancer. Now, researchers from CHU de Rennes in Renne, France, have discovered a correlation between hysterectomy and increased risk for developing type 2 diabetes, especially among women under 45 years of age. The research, which has not yet been peer reviewed and published, was recently presented at the 2022 European Association for the Study of Diabetes (EASD) Annual Meeting in Stockholm, Sweden. https://www.medicalnewstoday.com/articles/women-face-increased-risk-of-type-2-diabetes-following-hysterectomy XX Gotta love this creative and possibly very useful question: when bear hibernate, why don't they get diabetes? They eat tens of thousands of calories a day, balloon in size, then barely move for months. To answer that question, Washington state University researchers went to work. To find out how, researchers drew blood serum from six captive grizzly bears—aged between five and 13 years—at the WSU Bear Center, a research facility in Pullman, Washington. They also collected bear fat tissue that they used to grow cell cultures in the lab. This experiment helped the team narrow down the bears' secret to controlling their insulin: Eight key proteins that seem to have a unique role in bear biology, working either independently or together to regulate insulin during hibernation. Because humans share most of our genes with bears, understanding the role of these eight proteins could teach scientists more about human insulin resistance, Perry says. https://www.nationalgeographic.com/animals/article/hibernating-bears-could-hold-a-clue-to-treating-diabetes XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX Couple of events coming up next week: Hope you are doing well! I'm reaching out about an upcoming virtual streaming event hosted by Dexcom on Tuesday, Oct. 4 that will feature an exciting OUS (outside the U.S.) announcement from Dexcom leadership and Dexcom Warriors around the globe. The diabetes community will have access to the event beginning at 8 a.m. BT / 3 a.m. ET / midnight PT on Oct. 4 at DexcomEvent.com. XX Do you want to learn how to think differently about your life with type 1 diabetes? Click this link to register now! ==> www.reimaginet1d.com Join Dr. Mark Heyman for the 2nd Annual ReImagine T1D virtual workshop on October 6 from 7:30p - 9:30p Eastern! ReImagine T1D will challenge you to reimagine what is possible in your life with T1D and give you a roadmap to help them get there. After attending this ReImagine T1D, you'll have practical tools and actionable strategies that will empower you to live a full, flexible life without letting the emotional burden of T1D hold you back. If you cannot attend the event live a replay will be available, but you MUST register! Click this link to register now! ==> www.reimaginet1d.com XX On the podcast next week.. I'll have more about Dexcom's announcement and you'll hear about how diabetes communities around the world pivoted during covid to better reach their people. Very cool stories from a recent conference featuring diabetes online and offline communities. This past episode is all about Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

It's In the News! This week's top diabetes headlines and stories include: cybersecurity risk cited for some Medtronic pumps, Omnipod 5 gets European approval, new data about the Freestyle Libre and avoiding hospitalizations, the new T1D Index and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX XX potential cybersecurity risk for Medtronic MiniMed 600 Series Insulin Pump Systems. The FDA sent out an alert for multiple systems including the MiniMed 630 G and MiniMed 670G. They say this is a potential issue and that there have NOT been any reports of actually unauthorized access. Medtronic has issued an Urgent Medical Device Correction on their own website notifying users as well as providing recommended actions. If unauthorized access occurs, the pump's communication protocol could be compromised, which may cause the pump to deliver too much or too little insulin,” noted the FDA's September 20 Cybersecurity alert. On their website, Medtronic provides the Urgent Medical Device Correction, a list of model numbers impacted by the issue, and a multitude of frequently asked questions for device users. Within these resources, Medtronic notes the issue was identified through an internal review and, while the event meets the definition of a recall, users are not required to return their devices. In a letter to users, which was signed by Chirag Tilara, vice president of Quality at Medtronic Diabetes, and Robert Vigersky, MD, chief medical officer at Medtronic Diabetes, the pair recommended all patients turn off the “Remote Bolus” feature on their pump if it is turned on, which is on by default. The letter also urged users to conduct any connection linking of devices in a nonpublic setting. Additional recommended precautions from Medtronic included keeping pump and connected system components within user control at all times, be attentive to pump notifications, alarms, and alerts, and immediately cancel any boluses you or your care partner did not initiate. The FDA urged those with questions to reach out to Medtronic at 1-800-646-4633, option 1. https://www.endocrinologynetwork.com/view/cybersecurity-risk-minimed-600-systems-alert-from-fda-medtronic XX Omnipod 5 gets the CE Mark, that's European approval for individuals aged two years and older with type 1 diabetes. This comes as Insulet presents new studies at the European Association for the Study of Diabetes (EASD) meeting in Stockholm, Sweden. https://www.businesswire.com/news/home/20220920005138/en/Insulet-Announces-CE-Mark-Approval-for-Omnipod%C2%AE-5-Automated-Insulin-Delivery-System XX Abbott says the Freestyle Libre system can help reduce diabetes-related hospitalizations. Data from the Real-World Evidence of Freestyle Libre (RELIEF) were presented this week. The retrospective study of the French national health claims database shows that the 5,933 people with Type 2 diabetes who were following a basal-only regimen and using the FreeStyle Libre system had 67% fewer ADE-related hospitalizations one year after initiating the FreeStyle Libre treatment. The data also show a 75% reduction in hospitalizations for diabetic ketoacidosis (DKA), a potentially life-threatening condition when glucose levels are too high for too long and ketone levels rise to dangerous levels in the blood, and a 44% reduction in admissions for severe hypoglycemia (low glucose levels). Further, the study showed sustained reductions in hospitalizations over a two-year period of FreeStyle Libre system use, regardless of whether the patients were under the care of a diabetes specialist or a general healthcare practitioner. https://www.mddionline.com/diabetes/can-abbotts-freestyle-libre-help-reduce-diabetes-related-hospitalizations XX A look at bone health and type 1 diabetes in teen girls. Small study herewith girls age 10-16.. found that the more sedentary had worse markers of bone health in imaging tests than girls without diabetes. When the groups had the same physical activity, no difference was seen regardless of diabetes. However, this is early research and further study is needed, the group cautions. However, if further, rigorous studies confirm these findings, "physical activity is potentially a really effective means of improving bone quality in kids with type 1 diabetes." https://www.medscape.com/viewarticle/981092 XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX DRF, a global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index). The T1D Index is a first-of-its-kind data simulation tool that measures the human and public health impact of the T1D crisis in every country across the globe. Until now, there have been wide gaps in the data about the incidence and impact of T1D. Leveraging data and insights from the T1D Index can help change the lives of people living with T1D by identifying attainable country-by-country interventions including timely diagnosis, accessible care and funding research that could lead to cures. The T1D Index and accompanying research has been published in The Lancet Diabetes & Endocrinology. T1D is an autoimmune condition and one of the fastest-growing chronic health conditions, impacting nearly nine million people across the globe. Certain factors like family history can increase risk, but it is not caused by diet or lifestyle. T1D causes the pancreas to make very little insulin or none at all—this means the human body cannot convert food into energy, which can lead to long-term complications including damage to the kidneys, eyes, nerves, heart and even premature death. There is currently no cure for T1D. "As a member of the T1D community, I know many are not as fortunate as I am to have the resources necessary to live a healthy and fulfilled life," Aaron Kowalski, Ph.D., JDRF CEO, said. "This is why I am so proud that significant progress has been made to understand T1D's global impact through the T1D Index. We are calling on government and public health decision makers throughout the world to utilize the tool to identify and implement interventions that can change the trajectory of T1D." JDRF collaborated with key partners and experts around the world to develop the T1D Index—using the results from a global survey of more than 500 endocrinologists and 400 publications to simulate the state of T1D globally and at the country level. The Index uniquely illuminates the human burden of T1D by highlighting "missing people," which is the number of people who would still be alive today if they had not died early due to complications from T1D, and "healthy years lost," which represents time lost to ill-health, disability or early death from living with T1D. Simulations from the T1D Index suggest that globally, as of 2022, there are more than 3.86 million "missing people" and an average of 32 "healthy years lost" to T1D per person, if diagnosed at age 10. T1D presents a profound human, emotional and financial burden for those who live with it—and prevalence is on the rise. Simulations from the T1D Index have led to the identification of four key interventions that could change the current trajectory for T1D and its impact on people around the world: Timely diagnosis: enabling better education and training for medical professionals to accurately diagnose T1D. If the global population has access to timely diagnosis from 2023, 668,000 more people could be alive in 2040. Insulin and strips: creating barrier-free access to insulin and blood glucose testing strips. If the global population has access to insulin and testing strips from 2023, and coaching to self-manage the condition, 1.98 million more people could be alive in 2040. Pumps and CGMs: ensuring everyone living with T1D has access to technology that automates glucose monitoring and insulin delivery. 673,000 more people could be alive in 2040 if everyone with T1D has access to the technology available from 2023. Prevention and cures: making the case for further investment and research in emerging prevention, treatments and cures. 890,000 more people could be alive in 2040 if we find cures. Once interventions are identified on the global and country level, the T1D Index encourages users to take action by sharing the data and findings with their networks and local decision makers, and connecting with other T1D advocates in their communities. Additionally, the T1D Index shines a light on important statistics about the burden of T1D globally, including: Since 2000, T1D prevalence has increased at four times the rate of global population growth. The expected number of people living with T1D in 2040 will be 17.43 million. The number of "missing people" in the year 2040 is projected to be 6.85 million. https://medicalxpress.com/news/2022-09-global-diabetes-index.htmlXX XX

Episode 96Yoni Kozminski is the Founder and Chief Executive Officer of Escala, MultiplyMii, and several successful, yet less noteworthy ventures. Before building Escala and MultiplyMii, he helped scale an Amazon business from 2 million to 5 million in 1 year, leveraging his experience in digital agency. His career has mostly revolved around digital marketing and creative advertising in Australia, Israel and Los Angeles working with Mercedes-Benz, MasterCard, Sony, Medtronic Diabetes, Mondelēz International, and other eight-figure eCommerce brands.Listen to Yoni and learn how to hire A-players from the Philippines![00:01 - 04:34] Opening SegmentLet's get to know Yoni KozminskiYoni talks about his journey into the ecommerce industry[04:35 - 14:43] Where to Start in the Hiring ProcessHow solopreneurs can start in their hiring processWhy hire virtual assistants from the PhilippinesHere's a role that is so important in a business according to Yoni[14:44 - 24:30] Building Your “Dream Team”Building your “dream team” for your businessYoni talks about the services offered by EscalaHis reasons for starting his podcast, Successful Scales[24:31 - 29:38] Inventory Management The Right WayYoni gives a few important tips about managing your inventoryWant some Amazon refunds? Check out GetidaPromo code: FTM400How to build your Standard Operating Procedures the right way[29:39 - 34:22] 3 Components of the Business That Should Work TogetherHere's what many entrepreneurs are doing wrongThe 3 components of a business that have to work harmoniouslyConnect with Yoni. Links below[34:23 - 38:46] Closing Segment Know more about Yoni in the Fire Round!Final words Tweetable Quotes:“We look at how to systemize the businesses based on people, process, and technology. Those three have to work harmoniously.” - Yoni Kozminski“...if you got a great job today and you're thinking about firing the man, your worst possible outcome is that you have to go back and work for someone else...it's not really that much of a risk.” - Yoni KozminskiResources mentionedThrasioMultiplyMiiSellersFunding8figHelium10Yoni's podcast: Successful ScalesBooksThe 4-Hour WorkweekWho: The A Method of HiringEmail yoni@weareescala.com to connect with Yoni or follow him on LinkedIn. Check out Escala to unravel the hidden potential of your business!------------------------------------------------------------------------------------------Send us a voice message and let us know how we can help you fire the man! FacebookYouTubeInstagramEmail us --> support@firingtheman.comLEAVE US A REVIEW!

Ali Dianaty is Vice President of Product Innovation at Medtronic Diabetes and reflects on the explosion of developments for treating diabetes that has allowed patients to manage their diabetes in a way that fits their lifestyle. Ali explains, "We also make smart insulin pens, which allow people to do a better job of dosing their insulin. Of course, one of the big fears is that insulin can be a very dangerous drug. Think of it as if you give yourself too much, you can put yourself into harm's way. If you don't give yourself enough, it's the same thing. So, dosing that properly is super important." "We offer pumps that help do that more automatically, as well, in terms of dosing that insulin. And then, we also offer continuous glucose monitors that measure how much glucose is in someone's body. Then ultimately, we bring all of that together into some sophisticated algorithms as a system to automatically dose people's insulin. So again, with the premise of forgetting their disease. All of these things are intended to try to minimize the work going into managing diabetes, and quite frankly, to make things easier for them." @MDT_Diabetes #Medtronic #Diabetes #t1d #t2d #Diabetestech #DiabetesManagement #Type1 #InsulinPump #CGM #medtech MedtronicDiabetes.com Listen to the podcast here

Ali Dianaty is Vice President of Product Innovation at Medtronic Diabetes and reflects on the explosion of developments for treating diabetes that has allowed patients to manage their diabetes in a way that fits their lifestyle. Ali explains, "We also make smart insulin pens, which allow people to do a better job of dosing their insulin. Of course, one of the big fears is that insulin can be a very dangerous drug. Think of it as if you give yourself too much, you can put yourself into harm's way. If you don't give yourself enough, it's the same thing. So, dosing that properly is super important." "We offer pumps that help do that more automatically, as well, in terms of dosing that insulin. And then, we also offer continuous glucose monitors that measure how much glucose is in someone's body. Then ultimately, we bring all of that together into some sophisticated algorithms as a system to automatically dose people's insulin. So again, with the premise of forgetting their disease. All of these things are intended to try to minimize the work going into managing diabetes, and quite frankly, to make things easier for them." @MDT_Diabetes #Medtronic #Diabetes #t1d #t2d #Diabetestech #DiabetesManagement #Type1 #InsulinPump #CGM #medtech MedtronicDiabetes.com Download the transcript here

Hoy con Pontón en MVS, platicamos con Alejandra Cuevas, líder clínico en Medtronic Diabetes, sobre un dispositivo que simula algunas de las funciones de un páncreas sano. Javier Matuk habla sobre la tecnología que implementaron en los JJOO Tokio 2020

Noncommunicable diseases, such as cardiovascular diseases, cancers, and respiratory diseases, wreak havoc on individuals, families, and communities. Almost three fourths of deaths from noncommunicable diseases occur in low- and middle-income countries, yet only one percent of healthcare spending is put toward NCD care. All across the world, poor and vulnerable communities cannot access the quality care, technologies, and medicines they need. What does it take to break down these barriers that burden so many of our neighbors?In this episode, Chris and Eddie are joined by Hal Beckham, Head of Finance at Medtronic LABS and Chief Financial Officer for Medtronic Philanthropy and Foundation. Medtronic LABS is a social business dedicated to expanding healthcare access to underserved communities and developing systems of care based on the unique contexts of countries such as Kenya, India, and Ghana. Beckham talks about the importance of corporate responsibility, his vocation and calling in the context of his career, and the impact of Medtronic's programs and technology.Resources:Learn more about Medtronic LABS here:https://www.mdtlabs.org/about Read more about the impact of Medtronic LABS here:https://www.mdtlabs.org/impact-1 

This episode is a conversation with a young CEO of two early stage companies who is all about scaling and process in growing your business. In the past year he has started and grown two businesses to over 100 employees (in the middle of a global pandemic).  He helps clients grow and scale with best in business management consultants and top tier metrics that show how the business is doing.  Do not leave your growth to chance.      About Yoni Kozminski   Yoni Kozminski is the Founder & CEO of MultiplyMii & Wildfire Creative (and several successful, yet less noteworthy ventures). MultiplyMii & Wildfire take on three forms: Staffing, Management Consulting & Digital Marketing. All his teams are based in the Philippines (including the staff we help place in YOUR business) and this is how they provide the best global talent at a fraction of today’s Western world prices. Prior to MultiplyMii & during Wildfire Creative, Yoni scaled an Amazon business from 2M - 5M in 12 months, utilizing his experience in Digital Agency Land to build a fluid process and a team of incredibly talented individuals in the Philippines that would have cost 6 - 7 x that for less capable first-world counterparts. The bulk of Yoni's career to date (10 years prior to Amazon & MultiplyMIi) has been spent in digital marketing and creative advertising in Australia, Israel and Los Angeles working with the likes of Mercedes-Benz, MasterCard, Sony, Medtronic Diabetes, Mondelēz International, and eight-figure eCommerce brands. Yoni Kozminski believes that in life, it must always be win/win. If at any stage someone is getting ‘the better end of the bargain,’ there is no partnership there.    https://thomsinger.com/podcast/yoni-kozminski   ***************

It's been a busy fall already for Medtronic; they've acquired Companion Medical and the FDA approved their 770G pump. Stacey catches up with Diabetes Group President Sean Salmon to talk about that and much more. Find out the difference between the 770G and the upcoming 780G, their plans for longer-wear pump insets and when they might have a no-calibration sensor. In Innovations this week, a new study showing the benefits of once a week basal insulin. It's called Insulin Icodec. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's new book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone      Click here for Android Episode Transcription Stacey Simms  0:00 Diabetes Connections is brought to you by One Drop created for people with diabetes by people who have diabetes by Gvoke hypopen, the first remixed autoinjector for very low blood sugar, and by Dexcom, take control of your diabetes and live life to the fullest with Dexcom.   Announcer  0:21 This is Diabetes Connections with Stacey Simms.   Stacey Simms  0:27 This week, catching up with Medtronic, we're talking about the newly approved 770 G, looking ahead to the 780 G, their acquisition of In Pen and how they think they've cracked the code on longer where pump in sets,   Sean Salmon  0:42 the things that are in insulin to keep it from going bad. The preservatives, if you will, are behind a lot of that sort of site actions that you get. So we're able to take that stuff out and have just filtered Insulet. a queue will deliver to the site. That's really the magic behind getting the extension of use.   Stacey Simms  1:00 That's Sean Salmon. He heads up Medtronic diabetes group. In innovations this week, a once a week basal insulin, how would that even work? This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show. I am so glad to have you if you are new welcome. Glad you found us We aim to educate and inspire about type 1 diabetes by sharing stories of connection. My son was diagnosed right before he turned to back in 2006. And we have his high school sophomore 504 meeting this week. Yeah, it's virtual. His whole school is virtual. I've shared on the show before he is part of a very large school district in the Charlotte, North Carolina area. And the whole district has been virtual. younger kids are starting to go back to school in October. They're staggering it right now High School won't go back in person until January at least that's the plan. So I'm really interested to see how they handle this 504 meeting. He's had one, you know, we've been diagnosed since he was two. So he's always had one. In our district. We have a separate DMMP a diabetes medical management plan that covers a lot of the basics that are maybe in your your child's 504, but I assume this will focus on testing. I don't know. I mean, he's home. So you know, he can go to the bathroom when he wants he can drink water when he wants. I'll share more about that though. Mostly, I think this is about keeping our place in the 504 for things like the ACT and the PSAT and all that testing and he is so thrilled, but it's going to be coming up. Another thing I want to tell you about real quick is Hey, in September, we saw a big boost of sales of the audio book of the world's worst diabetes Mom, you know, this is my book, it's part memoir, part advice, stories, real life stories about raising a child with type 1 diabetes. And the audible version has been very popular. And I'm telling you September, I don't know maybe end of summer and everyone decided to get an audiobook, but audible loves when that happens. And now I have two free copies to give away, you do not need to have an audible account, you don't even need to really start one here, you're not going to be signing up for something you can't get out of you do need an Amazon account. So if you want the copy, I'm not doing a fancy contest on social media, I probably should. But all you have to do email me Stacey at Diabetes connections.com put audio book in the subject line and I will give you the first two people who do so a free book will make it very simple there. If you're interested in perhaps the paperback or the ebook, you can head on over to Diabetes connections.com or it's on Amazon, whatever is easiest for you. One more thing and it's an apology. Last week I apparently mixed up when I was talking about Medtronic 770 and 780 G. We do clarify that in the interview here with Sean Salmon. But to be clear, the 770 g was recently approved in the US. It is basically the same as the 670 g except for the addition of Bluetooth connectivity for data sharing and remote monitoring. And as you will hear, you'll be able to update the 770 G and future Medtronic pumps at home just like your phone. Alright, Sean Salmon. With that and a bunch more we go down a laundry list, but first diabetes Connections is brought to you by One Drop, and I spoke to the people at One Drop, I was really impressed at how much they get diabetes. And it makes sense when you think about it. Their CEO, Jeff was diagnosed with type one as an adult. One Drop is for people with diabetes by people with diabetes, and the people at One Drop work relentlessly to remove all barriers between you and the care you need. Get 24 seven coaching support in your app and unlimited supplies deliver no prescriptions or insurance required. Their beautiful sleek meter fits in perfectly with the rest of your life. They'll also send you test strips with a strip plan that actually makes sense for how much you actually check One Drop diabetes care delivered. learn more, go to Diabetes connections.com and click on the One Drop logo. My guest this week is Medtronic Executive Vice President and President for the diabetes group, Sean Salmon. And we spoke just as the deal for Medtronic to buy companion medical makers of the In Pen was closing. So that is a done deal. Now, In Pen is a smart insulin pen, you're probably familiar with it, it keeps track of dosing and recommended dosing, sort of like what you'd get with an insulin pump, you still have to inject, but the dosing can be automatic, the app will tell you exactly what to do. And keep track just like an insulin pump does as well. We talk about that. And a lot more here. Here's my talk with Sean Salmon. Sean, thank you so much for joining me. There's a lot going on at Medtronic these days, I appreciate you spending some time with me and my listeners.   Sean Salmon  5:44 That's my pleasure. I appreciate the opportunity. Thanks, Stacey.   Stacey Simms  5:46 We're gonna go down pretty much a laundry list of technology and questions from listeners and things that they want to know. But let me start slow. And just ask you, how are you feeling about everything these days, we've got delays because of COVID. We've got, you know, a year like no other it's a cliche at this point. But you know, in your own words, how are things these days at Medtronic, and in terms of, you know, what you're looking at going forward?   Sean Salmon  6:09 Well, it's interesting, right? I think we're all living through some unprecedented times, just everywhere in the world right now. And it's certainly challenging. But at the same time across Medtronic, you know, I think we've got such a rich pipeline, and just about every single business, it's, it's exciting to see what you know, what the future is gonna bring, we get past some of these near term challenges. I've been here for 17 years, I can't remember a time where we had so much innovation all stacked up, ready to go   Stacey Simms  6:34 Well, let's jump in and talk about it. One of the first things I want to ask you about is the acquisition of companion medical. And this is the startup they've got the in pen. This is the I think my listeners are very familiar with it. And we've done episodes on it. So tell me a little bit about what the plan is, for companions in pen product with Medtronic, what are you gonna do with it?   Sean Salmon  6:59 Yeah, sure. Well, maybe I'll start out with, you know, why did we decide this was a good idea? And yes, I came into this role. Yeah, you whenever you start a new job, it's been about a year from now, the first thing you do is you formulate a strategy of how are you going to serve your patients in the market? And it's really, you know, strategy is really a question of, what are you providing for who, when you start asking those questions, it really narrows down what your focus should be in, and didn't take that long to sort of Peel apart? What is it that are people living with diabetes are seeking and how are they? How are they being treated today. And if you look around the world, it depends on the country you're in. But multiple daily injections is the most frequently chosen therapy, it's something that ranges between 60 and 90% of the treatments that are out there. So you know, really the philosophy app is that for us to know, what are provided for whom we need to know, you know, where do people where are they on their journey? And where do they want to go. So, you know, injection in and of itself is a fine therapy. But there's just really variable outcomes that patients are being able to get from that. And a lot actually about just the, it's made difficult by the fact that you really don't always know how vigilant you are, how much insulin you've taken, how much you have on board. And it's very hard to keep track of all that. And what companion has done with the implant system, of course, is to track that insulin, so you know exactly how much is given at the right amount of time and have some estimation for carbohydrates, the ability to load that up. And then of course, the CGM data is there. So when you have those components, a lot of that difficult math calculation about how much insulin Do I need to take at a given time is made simpler. And we can extend that by adding a lot of what we have within our automated insulin delivery systems, algorithms, personalization of those algorithms into that experience with a pen. So if you will, we're trying to close that open loop, or at least close it down some and what we do with automated insulin delivery systems as we have this track record, right, have you just recording CGM data over time, and knowing what the influent amount is, you can really get to an understanding of how individuals kind of respond to insulin, and more personalized, the amount of dosing that happens. So get an even tighter connection to how much insulin someone needs to take at a given point of time. Of course, on meal handling, that's the place, we're really pushing a lot of our technology, we have a very large and capable group that does data science and artificial intelligence. And all that really means is that we're able to take large data sets, and then put them into actionable insights that really simplify how people can get better control without having to do anything. And one of the really interesting areas we're investing in right now is around meal handling. So we can with our technology have a really good sense of when you're going to eat. And we can confirm that some gesture control technologies that come from a wearable like a Fitbit, or an apple watch or something like that. That tell us can confirm that some is eating. So in that instance, you could, for example, remind people, there's been no bolus given that it's time to bolus. And if you miss just two boluses a week in a meal, that equates to about a half point increase on the A1C. So obviously, outcomes can be made better. But the important thing is that it's done in a sort of an invisible way or helpfully in the background way. We're not asking somebody to anymore, which I think is really the sort of driving principle behind what companion medical set out to do within pen spec, this least burdensome as possible? Well, we can add a lot of technology that isn't visible to the user, for the most part, but can really drive a better experience and better outcomes. So what we're trying to do with a closed loop we can bring to this open loops, I said, and that's really, I think how the two fit together can help it a lot of ways.   Stacey Simms  10:58 A couple of questions about You just said you. You mentioned the gesture technology. That's Klue, right. You all acquired Klue this year.   Sean Salmon  11:03 Yes, exactly.   Stacey Simms Is that going to be part of a companion medical system?   Sean Salmon Yes. So the idea is, we're going to have that for any means of insulin delivery, right. So it's the ability to detect that somebody is in the process of eating. And the absence of any kind of bolus is a great opportunity to say here, let me give you a helpful tip here and remind you to bowls, whether you're pushing a button on your pump, or you're, you're reminding yourself to bolus we can drive some improvement there. And it was evaluated in a recent study that we did. It's a small study. But we showed that we could fact drop a one suit by a fairly sizable amount just by bolus reminder. Now, ultimately, I think we can use Klue and that technology in a way that can actually automate the delivery of bolus so nobody has to do anything within a sort of closed loop system. But you know, that's, that's some more work than where, or whatever to do it. Absolutely. It's   Stacey Simms  11:53 you heard me laugh, because, you know, just by bolus reminder, parents around the world have children with Type One Diabetes would argue with you that a simple bolus reminder in the form of a parent does not make that much of a difference. Yeah. But I hear you, I   Sean Salmon  12:07 think it Yeah, I mean, the difference here is the bolus reminders, and just it's time to bolus what we can do. Knowing the history of how much insulin is on board. Get a quick estimation is the medium small, large amount of carbohydrates being consumed, we can tell you how much to bolus not just that you need the bolts, right? which we think is a helpful insight.   Stacey Simms  12:28 When you talk about Klue. It also makes me laugh as you listen. As I talked about Klue, we did an episode with them in the past if you'd like to learn more, and Sean , I laugh because every time I talk about Klue I do the gesture of eating food. I don't you can't see me but every time I mentioned it, I think that's because that's how it was explained to me when they first demonstrated it. It's a really interesting technology. But that'll be in not just pens, you're planning on using that in pumps as well.   Sean Salmon  12:53 Yeah, so you know, Klue actually runs on on a wearable. And then it talks to the algorithm that's either you know, on your phone for your pen, or can be the algorithm that's driving the automated insulin delivery system. So think of it like a sensor, and the sensor gives input so that the algorithm knows what's happening. And it lends itself to any means of insulin delivery.   Stacey Simms  13:15 One of the big concerns and you know this when a large company buys or acquires a small company or product the big concern is that you know, it'll be shelved or there will be big changes to make it more proprietary. The in pen is now used with Dexcom and the ever since implantable CGM. Can you reassure people who are using it right now that you're not going to change that I assume it'll be used with a with a Medtronic sensor, but will you continue with the sensors that it is integrated with right now?   All right, right back to Sean answering that question. But first diabetes Connections is brought to you by Gvoke hypo pen, and almost everyone who takes insulin has experienced a low blood sugar and that can be scary. A very low blood sugar is really scary. That's where Gvoke hypo pen comes in. It's the first auto injector to treat very low blood sugar Gvokek Hypo pen is pre mixed and ready to go with no visible needle. That means it's easy to use in usability studies 99% of people were able to give Gvoke correctly. I'm so glad to have something new. Find out more go to Diabetes connections.com and click on the G voke logo. gvoke should not be used in patients with pheochromocytoma or insulinoma visit gvoke glucagon comm slash risk. Now back to Sean , talking about Medtronic plans to continue in Pen with its current partners.   Sean Salmon  14:44 Yes, we have no plans to take away anybody's sensors from them. But we're not entirely in control of that. So if if sensionics and Dexcom plan to maintain that access and then we're game we want to make sure that people have the support they need   Stacey Simms  15:00 When you say you’re not in control of it, you’re talking about what Dexcom and Eversense would do,  you're not talking about something on your side.   Sean Salmon  15:07 No. So the way all this works is you have to have, depending on what platform of phone you're dealing with, you have to have a thing called an API, which is basically a hook of software into the algorithm. So somebody on Sony decides they don't want to have that access to the longer they can turn it off. But we're not going to turn it off. We don't have control over that. So our belief is that, you know, if we're meeting patients where they are, and they're on a Sensionics device, we should maintain that access for those patients. Of course, we want to open up access to our own CGM. So we have a lot coming in the pipeline for CGM, which is pretty exciting. But no, I understand the sentiment that when you a large company buy something that they want to shelf it This isn't like big oil buying biofuel. Right now we're, we think we're gonna bring a lot better experienced to patients by combining the best of what companion has developed an impact with what we're endeavoring to do with things like Klue and neutrino and a lot of other personalization algorithms that be used in the closed loop side.   Stacey Simms  16:08 So let's talk about sensors. Let's just pivot right to that first, though, before we let this whole thing go within any timeline and integration with the guide. assume it's with the Guardian, CGM.   Sean Salmon  16:17 Yes, so initially, we'll have Guardian, but there's no we have three or four, five actually different generations of sensors coming and it's going to be compatible with everything we develop going forward as well.   Stacey Simms  16:30 Let's talk about Guardian Connect. This is the standalone CGM doesn't need to be paired with an insulin pump. Tell me a little bit about the reception of that, what the plan is for it. And you know, Who is it for?   Sean Salmon  16:41 Yes, so I think a standalone Guardian has been sort of an on ramp to be able to use an integrated CGM with our pump. But frankly, I think the experience that we've provided with that needs a lot of improvement. That's what we're endeavoring to fix with the pipeline. And there's two parts to that one is finger sticks, you know, to, to calibrate or to confirm before dosing as required finger sticks, and that's something that we are trying to remove in the next generation. And the other one is on just the, the ease of putting it on. And it takes a lot of overtaken steps to insert, and generates a lot of trash in the process. So all of that's problematic. And we're, we're moving to an integrated platform where the sensor, and the transmitter all in one, easy to apply three step, just press it on your body kind of approach. And in the interim, reducing or eliminating the need for finger sticks. That's what the near term pipelines about and then longer term, we can take the size of that down even further, we're already taking about 50% of the volume down from one move to next, we can get a lot smaller than that we have some really interesting technology that uses something called a wafer fabrication, which just means you can make very small electronics in a very highly repeatable way. So you take a lot of variation out. And then of course, you know, making sure that we're continuously improving the reliability and the wear life of these devices. There's a lot of technologies we have aimed at to to ensure that that happens. And simple things like we spend a lot of time money and effort developing patches is going to stay there, you know, the adhesive that won't interfere with the skin, but will stay there through very difficult conditions. And it took a lot of engineering, we actually did a lot of work in the fields in South Florida, just you know, high humid, very hot heat to make sure that we would have this he's up just right. So there's a lot going on in the CGM side of things. That's pretty intriguing.   Stacey Simms  18:40 I'm curious, and this is a very specific question. These future generations, any plan to go straight from a CGM sensor to a watch, that's something that just seems to be very difficult, you know, no phone involved in between? Nothing like that.   Sean Salmon  18:55 Yeah, no, it is difficult. And it's difficult for a lot of reasons, including power management of how that that Bluetooth connection is different than one to a phone. So I think as as watches evolve, and maybe that technology changes and the ability to kind of talk a lot of this on the kind of wearable side of things. It's not entirely just what can you do with your CGM, your algorithm said some, it is more complicated than you'd think, you know, hopping from phone to watch that takes the processing power and the connectivity that's already there. But think of it like a highway, right? There's like so many lanes have a highway that you can drive a car on. And if the watch is already tethered to one, one connection by Bluetooth to your phone, you've got fewer lanes available, other connections. So that's really, you know, it's I don't get too technical about it. But that's really the the near term challenge. But you know, I think there's strong interest in this. And as the wearables progress, I think we'll have the opportunity to to do things like that. But right now, it's just complicated.   Stacey Simms  19:56 All right, let's talk 770 g This was approved by the FDA in August, and it's down to kids as young as two, my understanding was for the approval. Now I'm this is gonna pardon my take on this. And this is for all of the pump companies. I wish you guys would call your pumps, something that told us more about it. I don't know if it's a medical device thing, and I have this problem with Omnipod and Tandem and everybody else. But you know, it's all numbers. So tell us a little bit about what's different from the 770 g to the 670. And then to the 780. Like, right, what's different about this pump?   Sean Salmon  20:33 Yeah, so the the biggest difference other than age education, which does, you know, it's still indicated for people over the age. I think there was some confusion at first said it's just for kids, and it's not Oh, kids. Yeah, so I, you know, I think that the biggest difference is really the inclusion of Bluetooth connectivity with this with this device. And that does a number of things. So first and foremost, it allows a person or a parent or caregiver to see the CGM pump date on a film. So we we've been lagging in that competency. Now that's available. It also allows the carelink system which is our management system glucose to automatically update so that you can do things like telehealth visits, right. Or if somebody's going to the doctor's office, rather than that, that kind of interruption to the workflow where the pump has to be connected and then downloaded, that really slows down that visit for for the person that's, you know, at the visit, it slows down the workflow for the health care providers. So the ability to take that connection and automatically upload it at your convenience without having to do anything, is what that connectivity brings to us as well. And then finally, it goes all the way to we can when software becomes available, make upgrades. Or if you have to patch something knows you know how to get out of your phone, where they'll have a new version to patch up something, you can just push that over the air. So we have that capability to upgrade future algorithms without having to connect anywhere.   Stacey Simms  21:59 So just to be clear, this is like what we do with the Tandem X2, you plug it into the computer, you get the latest download, it changes the software in the pump, and then you're off and running. Same thing, plug it in,   Sean Salmon  22:09 that was what one big difference, we'll plug into the computer, it goes over the air, just like you can update your unit up to your phone over the air today. If you changing your operating system, it's the same idea. You can do this without having to have a computer or having to plug cable in,   Stacey Simms  22:24 do you need a doctor's prescription for changes? Or is that a change by change? I would assume there might be?   Sean Salmon  22:30 Yeah, it depends on the change. So if you're talking about, you know, a security patch, you don't need a prescription for that, if you're talking about moving to the next algorithm, like the difference from 770 to 780 is really an algorithm change. It's the same hardware platform that would require a prescription.   Stacey Simms  22:45 So let's talk about the 780 which is the I assume this is the next thing in the pipeline and following the numbers.   Sean Salmon  22:52 Yes, so we we have released the adult data for the 780G, which at is about the algorithm now at the American Diabetes Association began this year virtually. And really, there's a couple of differences here. What this device does now is it takes the Ability Beyond just basal insulin, but also to bolus where you can the situation where there's rising glucose, the algorithm can bolus every five minutes to control. Somebody maybe missed a meal bolus, so they miscalculated how many carbs they ate, for example, and blood sugar still rising, we can predict where it's going to go both correct it without stacking up insulin. So what all that means is we can drive better time and range when there's there's missed boluses or miss calculations on carb counting. That's one big difference. The other big difference is the target that you set these two, so you can set a target, as you may know, on the 670 G, the target you can set is 120, we can still set a 120 target on this algorithm. But we can also set that target of 100. And the clinical results that we showed, were clear that you could take the target lower without increasing the risk of hypoglycemia. In fact, it was so numerically lower rate of hypoglycemia. So this, this algorithm, I think really gives a lot more freedom. And that's, I think the biggest thing that we were looking for all these are great, you know, time and range, we've been leading that the industry and being able to provide the best time and range, but the user experience got a lot better. And a lot of it had to do with alerts and alarms and all the things that we did. And I think To put it simply, there was a belief as the first hybrid closer algorithm out there, that whenever something goes awry, that you should kick somebody out of what was called auto mode and have them go confirm something with like a finger stick. Because I think the belief at the time was that you know, you can't trust his algorithms take care of somebody, and a person is better off better able to manage their diabetes than a machine. And I think that was probably a fallacy. As it turns out the algorithm that what we change here is we just aren't kicking people out. We are waking people up in the middle of night do things the algorithm pretty good at smoothing things out without causing any new troubles prevention. So a lot of that, I think out of abundance of caution safety alerts, kicking people out asking for fingerstick calibrations was unnecessary. And we're seeing a big reduction in all of that and very high satisfaction among the people in a clinical trial. And we've launched it in a limited way in Europe so far, and feedback has been really tremendous. This is a very big improvement of what we had been offering a couple   Stacey Simms  25:25 of just questions for clarity, Sean , the you're talking about the algorithm in the 780? Right, the 770?   Sean Salmon  25:32 Yes, that? No, that's 770 is basically the 670 algorithm. The big difference is really that indication of age, as well as the the ability to upgrade   Stacey Simms  25:44 software. If you want a pump right now that you can then upgrade when the new 780 algorithm is available. It's got to be the 770 you can't upgrade. Yes,   Sean Salmon  25:54 yes, you're correct. Okay.   Stacey Simms  25:56 Um, to that end, just again, just to clarify, are there other ranges you can set? Is it totally customizable down to 100? Or is it 120, or 100.   Sean Salmon  26:06 So you can choose, you can choose either target, but you can adjust other settings like the part ratio like insulin sensitivity factor. So there's some customization that can get there. And we ran, I think, three clinical trials. And we're currently doing what we call a continued access study in the US where we're trying to optimize those settings, to make sure that we can get the very best experience for people with the pump. And I think what we've learned is there's a lot of these other settings that we can give more help to the endocrinologists to be able to set those but right now, those settings are, are the endocrinologist job to go fix, we can give them suggestions. But the user themselves can't make those adjustments as easily.   Stacey Simms  26:46 Wait, I'm confused. The endo can make some changes, but the users can't.   Sean Salmon  26:50 Yeah, so there's certain things again, it's about making sure that people are safe, where we could recommend changes, or the algorithms can change things along the way. But there are certain settings like these carb ratios and everything else that need to be dialed in. Yeah, but   Stacey Simms  27:03 the user can do that. Right. I don't have to bring the pump to my endocrinologist and say, I Well,   Sean Salmon  27:07 they can, but they should they should make sure that you're talking to   Stacey Simms  27:11 Got it, yes, no, no with it with the guidance of an endocrinologist, but you're not going to make me get a prescription to change my carb ratio.   Sean Salmon  27:17 No, no, no, I think it's just that we can really fine tune the system. But rather than experimenting on yourself, I think we can give some help to know what are the optimal settings for you. And that's know something we call personalized closed loop is, we could do that automatically in the background without anybody talking to anybody. That's one of our future pipeline projects, we can also tell you from the history of your glucose and insulin data, how you can get a little bit better precision for somebody. And I think that's what we're trying to do on the carelink side of things. Here's the ability to really dial this in the right way. I think that for some endocrinologist, that's not going to be helpful, right? They're very, very good at this to do it all the time. And then there's others who don't really have large type one populations. And they could use a little bit of light called the teachers edition of the textbook, to help them make sure that they're doing the best for patients.   Stacey Simms  28:08 I think that sounds wonderful. I just think, you know, this podcast audience is a little bit different, or I shouldn't, it's a lot different. This is an incredibly well educated audience that is going to get a pump like this, and mess around with it themselves at home and see how much they can change it. In fact, as you know, part of this audience is going to physically try to probably break into the pump and see what they can do with it. So I know you can comment on that you don't have to comment on it. But that's why my hackles went up when you said the endocrinologist can, but I get what you're saying for the vast majority of people with diabetes, the endocrinologist or even their general practitioner, which is different story altogether, is really going to be the guiding hand here. Just another question you mentioned with the 780. The change from, you know waking people up kicking out of auto mode, fewer calibrations, is that really in the works in terms of fewer or no calibrations or that's a hope for a future sensor?   Sean Salmon  28:58 No, that's absolutely in the works for the sensors. So we we have a product in that's complete as clinical trial and other ones very close to doing that. That eliminates or vastly reduces fingerstick calibrations? And then yeah, so it depends on the regulatory claims that we make on that specific device. And then we have two others in the pipeline that absolutely eliminate finger sticks altogether. Now, that doesn't mean that you know, if you get a reading, it doesn't make sense to you that you shouldn't go confirm it, the glucose, the blood glucose, then calibrate No, no perfect sensor. But yeah, our algorithm itself that goes into 770 cuts down by about half the number of requests for finger sticks with the same sensor. And then when we change the sensor, we can, we can largely eliminate that unless there's something that needs to be confirmed, because the reading doesn't make sense.   Stacey Simms  29:53 So is the hope that the 780G would launch with, I hate to compare it to Dexcom but let's just go ahead and do that. Cuz that's what we're all talking about here anyway, obviously, most people who use a Dexcom understand that it's not infallible, you do have to double check, sometimes, you know, you'll get a sensor error when it doesn't understand what the you know what it's getting the information that it's taking in, it'll stop working, that kind of thing. So is the hope to launch the 780G system with a sensor that's comparable to what I just described.   Sean Salmon  30:20 So it's gonna depend on where you are in the world. But the 780 is going to be compatible with past and future sensors. So you know that they may be on different timelines. And we really try to think about this like it's a system to so we've got the pump, we've got the algorithm, we've got that sensor. And the other thing we have is the tubing set and reservoir. And there's another innovation we're bringing that allows you to extend the use of that on label of that tubing set from the typical two to three days. At the seven days. We call that the extended wear infusion said that's also known as clinical trial. And the goal is to have that also compatible then 780G algorithm. So the algorithm that's on that pump, which can have all that connectivity Vantage can work with this current and future pipeline of sensors, and be upgradeable on the infusion set is all sort of in a suite of what we're trying to bring together.   Stacey Simms  31:14 Well, Boy, am I glad you brought that up. Because I have said for years, and my son has been using an insulin pump for I don't know, 13 years now that the inset is the weak link of pumping. And I know, you know, a couple years ago, we were all excited about the BD flow was supposed to be this the latest and greatest, it didn't work out so well. So that went away. Can you tell us a little bit about what you found? When I hear longer? Where insets? I think, Oh, my gosh, you know, we've all been warned about infection and scarring and don't use the same site for that long. What are you finding?   Sean Salmon  31:47 No, it's a really good question. And you know, what is it that's so magical about it? How do you get to extend it? And without getting too much detail to the simple answer is that things that are in insulin to keep it from going bad, the preservatives, if you will, are behind a lot of that sort of site reactions that you get. So we're able to take that stuff out and have just filtered insulin if you will deliver to the site. And that's really the magic behind getting extension of abuse. And you know, we did a study where we, we measured this and about 80% of the study participants were able to get seven days your body is going to react a little differently being who you are. You see that with CGM, right? Some people can wear those things for two weeks, and other people can't. Because their body's more aggressive at attacking that foreign body response, just by comparison, for three days, which was our control arm 70% of people got to three days, right? So we've got a higher proportion of people able to make it seven days, we think it's largely due to getting out those preservatives that are the insulin to keep it fresh.   Stacey Simms  32:50 That's fascinating. It's simple as a filter. I've always thought that yeah,   Sean Salmon  32:54 it's not it's no, it's also your insulin is a very sensitive molecule too sensitive to temperatures, you know, and it's also sensitive to you know, how it's contained in the reservoir. So our rigid reservoir system doesn't like mechanically damage the molecule either. So that's, you know, an advantage that we've always had with our reservoir design, then you add to this, the ability to filter out the preservatives, and you get this extension to where so you can preserve a lot of insulin, use a little more judiciously, and of course produced it. You know, the difficulty of having to change your set every day. Maybe it's a fusion set Sunday, you change it once a week, and maybe same time of changing your your sensor as well. Who knows?   Stacey Simms  33:34 Well, I think that would be pretty amazing to have a longer wear inset. That works. Because a lot of people have trouble as you said, getting to three days. Yes. One of the big questions that came up in with my listeners when I told them I was talking to you, and we've covered most of them. But one of the big questions came up was Medicare, in terms of this technology is great. Will it be covered? Can you speak to that at all?   Sean Salmon  33:53 Which which part of Medicare you asked about? Are you asking about the Well, let's talk Yeah, more of a?   Stacey Simms  33:59 Well, I think the real question is everything. But let's talk about the the system. As you mentioned, you talked about it as a system, the 780 will the system be covered? Or will it be piecemeal?   Sean Salmon  34:09 Yeah. So the rules of Medicare are really around the designation of the sensor, can you make a claim of what's called non adjunctive, meaning that you know, you don't you don't have to confirm the CGM ruling before you dose insulin. So when you're 64 years old, and your pre medic quick care and you're on like a 670 g system today, your commercial insurance pays for the sensors, the tubing sets, the reservoirs, of course, did initial investment in the pump. When you turn 65 and you move to Medicare, you no longer can get the Guardian sensor paid for because we don't have that designation. For Non exempt. They've even though it's clearly driving the pump all day long every day. So we have to get that labeled claim for the sensors for everything to be covered. And that's what we're trying to do right now with the Guardian sensors and of course, the future pipelines. themselves. But like I think it's a, there's a couple different efforts on that. But it is a little bit of an idiosyncratic thing that that exists in Medicare itself, just the way the payment law works. And we're trying to get that changed,   Stacey Simms  35:14 has COVID, delayed studies, submissions, things like that for you, while   Sean Salmon  35:19 at the branch of the Food and Drug Administration that regulates diabetes face is also involved in a lot of things COVID related, including like the in vitro diagnostic testing, and that sort of stuff. So yes, I'd say on the medical reviewer side, in particular, there's been just a difficulty for them to service all the kind of pre market or new devices that are coming through while doing this difficult work of making sure that all the COVID tests and things related to that are done. So yeah, there's been something that has been a little bit challenging. And of course, in the clinical trial environment, we actually had a couple of trials going on during COVID. And some of them have gone pretty well. Honestly, I think people are stuck at home and not willing to participate the trial. It's not been like that. In other parts of Medtronic, we've got a lot of the hospital based studies have been very difficult and highly impacted by understandably, people's fear of going to a hospital for for anything right now is pretty high. So I'd say it's been a mix. Like we've had really good collaborative conversations with FDA making sure that we streamline and make it as simple as possible as we submit new dossiers. But there is really a constraint at that medical reviewer level that's been, you know, difficult for the entire industry.   Stacey Simms  36:35 You've been so generous with your time. I really appreciate it. I just have one more question for you here. And that's about tide pool, about a year ago, maybe more now, Medtronic and tide pool announced that they'd be working together on a, you know, a future interoperable, closed loop. And it would be a separate system from the seven at any update on that.   Sean Salmon  36:55 Yeah, we're worth continuing to work with tidepool. There's a joint steering committee that we participate in. Our goal here is to create a Ace designated pump that runs the tide pool algorithm. But yeah, that collaboration is ongoing. We're working well with them. But I don't really have an update on that.   Stacey Simms  37:13 Well, Sean , I really appreciate it. There's so much going on. Do you know to talk about and thanks for keeping us straight with the numbers and everything else. I hope you come back on and you know, continue to explain all of these developments. But I really appreciate it. Sean , thank you so much for spending so much time with me for sure.   Unknown Speaker  37:28 Thank you, Stacey.   Announcer  37:35 You're listening to Diabetes Connections with Stacey Simms.   Stacey Simms  37:41 We talked about a lot of stuff there. There is a lot more information as always over at Diabetes connections.com. You can learn more on the episode homepage about everything that Sean talked about. I'll link up some stuff to Medtronic into some other studies. I said a couple of weeks ago, there's something about September, October. It's like all summer long. Yeah, we have the ADA and we have the different conferences. But then every year at this time, I feel like oh, it's kind of slow, nothing's happening. And then I get all the tech companies in the fall. So I'm excited to continue to bring you as much information as I can. I have more interviews coming up. We just talked to Dexcom. I'll also be talking to Abbott. I'd love to get Omni pod that folks from Insulet back on here. So we'll we'll see what we can do. But in the weeks to come. definitely let me know if there's particular technology you want to hear more about. I love talking to these companies. It's always fun to get a kind of a peek under the hood. And I like hearing the voices and the stories of the people who are in charge of this stuff. I appreciate them coming on not everybody does you know that but it's great when they can answer your questions. And I love doing that. So let me know if you want to hear from and let me know what you want to know. All right innovations in just a moment with that once a week basal insulin that's being tested. We'll we'll talk about that. But first diabetes Connections is brought to you by Dexcom. And when you have a toddler diagnosed with type one, you hear rumblings for a long time about the teen years when it hit us full force a little early. I was so glad we had Dexcom you know Benny's insulin needs. I've shared this. They started going way up around age 11. And when I say way up, I know some of you parents out there with little ones think maybe we increased by point two or something like that, because I remember those days Benny's first basal rate was 0.025. That's how much basically got an hour. But by the time between ages 10 and 12, his basal rates doubled. And between 12 and 13, they doubled again. So along with the hormone swings, I really can't imagine managing diabetes during this crazy time. Without the Dexcom continuous glucose monitoring system. We can react more quickly to highs and lows. see trends adjust insulin doses with advice from our endocrinologist. I know using the Dexcom g six has helped improve Benny's A1C and overall health. And by the way, he's almost 16 and those insulin needs have already started going down. This is wild. If your glucose alerts and readings from the G six do not match symptoms or expectations. Use a blood glucose meter To make diabetes treatment decisions to learn more, just go to Diabetes connections.com and click on the Dexcom logo.   Innovations this week, a once weekly, basal insulin. This is something that was announced earlier this summer. I don't know about you, but it's snuck by me It was announced at the ADA Scientific Sessions, Novo Nordisk announced that a once weekly insulin Icodec had performed as well as Lantus in a 26 week trial. Now, this particular study was done with people with type two diabetes. But before you dismiss it, there has already been a trial of people with type one diabetes, and novo expects to submit and get this and hopefully FDA approved for people with type one and type two diabetes, I couldn't find a lot of information about the previous trial with type one, there is another one that completed over the summer, hopefully, they'll release the information on that maybe some of you who are more savvy in the ways of clinical trials can dig it up the Can you imagine once a week basal insulin, I mean, obviously, the benefits of that would be incredible. And also thinking about it for people who like to go untethered using basal insulin from an injection along with an insulin pump, which is something we did for two years. And even with control iq and you know, more advanced hybrid closed loops. Just talking to Medtronic about there's, I know a few people who like to use untethered with it, who find that there's just something about getting that always constant, steady, basal insulin smooths everything out. And certainly when you get into the enormous elephant doses that Benny was taking for a while, it helped tremendously to take that load off of the pump. I mean, between his weight loss and you come in at a puberty and I know he loves when I talk about this stuff, his insulin needs have come down incredibly, and certainly to the point where we didn't need to stay on untethered, but I think it's fantastic, it's a great option to have and once a week, basal insulin makes that a lot better. So I will keep you posted if I find out more about the type one trial, but is called insulin Icadec. If you have something for innovations, please let me know this can be a hack that you thought up a tip or trick something with technology or new influence. You can always email me Stacey at Diabetes connections.com. I mentioned Benny's 504 Review earlier in the show. And that happens later this week. He's also got an endo appointment this week. lots going on. I don't think the endo appointments going to be too exciting, hopefully. But you know, we do check in every quarter. And I think to mix it up, my husband is going to take him this time. Slade rarely goes to the endo usually because he's working in busy and and it's been on me for the last couple of years, which I love to do. I really like catching up with our endocrinologist who's become a friend. But I think I'll let the boys go. And gosh, you know, another reason not to go. I'm looking at making sure my door is closed. So Benny can't hear me. You know, the kid has this permit, and he's gonna be getting his driver's license if he passes in January. And I know Slade will let him drive to Charlotte, which is like a 40 minute drive. So he can do that. I don't need that stress of sitting in the front seat and putting the mom's seat belt right throwing my arm out, which I cannot believe I do. But I've done it with both of my kids. Oh, I remember my mother doing that clear as day. I don't even know if they're doing driving tests here. They haven't been. I know plenty of kids who got their licenses this year, because of COVID. They're not actually giving them a driving test. They're just saying, oh, did you do your hours? Alright, here's your license. And it's a graduated system here in North Carolina. So they can't get their afternoons they can't drive at night until they take an actual driving test. I don't mind goodness. All right. So let's keep you posted and updated on next week. We'll see how much he lets me share. Thank you so much to my editor John Bukenas from audio editing solutions. Thank you so much for listening. Don't forget if you want the free audio book, email me Stacey at Diabetes connections.com subject line audio book, and the first two will get that promo code. Thanks so much for listening. I'll see you back here next week. Until then, be kind to yourself.   Benny  44:03 Diabetes Connections is a production of Stacey Simms Media. All rights reserved. All wrongs avenged

Ira Pastor, ideaXme life sciences ambassador, interviews Rick Bente, MSc, MBA, BS, CEO of Seventh Sense Biosystems. Ira Pastor Comments: Getting blood drawn is not a fun activity for many. It can be scary for some (especially if you have children); it can be painful for others (especially where frequent blood draws are required). Studies show that a remarkable 20% of the population has some degree of fear of needles or injections, and 10% within that number suffer from what is known as Trypanophobia (a psychological term for people with an extreme fear of medical procedures involving injections or hypodermic needles), who on top of their anxiety, completely avoid necessary tests and treatment. In addition to this, it is estimated that needles injure healthcare workers more than 2 million times a year in accidents, with potentially dangerous and deadly outcomes. Drawing blood is likely the most common invasive medical procedure, with an estimated half a billion a year conducted in U.S. hospitals alone, and two to three times this number across all hospitals worldwide annually. On top of that, millions of patients have to prick their fingers daily, multiple times a day, and experience pain each time. Seventh Sense Biosystems: Seventh Sense Biosystems is a company that has designed and developed, the world's first push-button blood collection device, called TAP, which aims to make the process simple, convenient, and virtually painless. As $50 billion is spent annually on diagnostics, combined with the fact that consumers are demanding more "quality of life" centric products from the healthcare system, Seventh Sense Biosystems is aiming to create a new standard for blood collection that increases patient compliance with testing orders, leading to faster diagnoses and better outcomes. Seventh Sense Biosystems was actually founded by one of ideaXme's previous guests: chemical engineer, scientist, entrepreneur, and inventor extraodinaire, Dr. Robert Langer, from MIT. Rick Bente: Today, we are joined by Mr. Rick Bente, CEO of Seventh Sense Biosystems. Mr. Bente joined Seventh Sense Biosystems in 2019 bringing a strong background in the design, development, and commercialization of disruptive medical devices. With over 15 years of experience, and more than 50 granted US Patents in the wearable medical device space, he has held a range of leadership roles in R&D, Marketing, and Business Development. Mr. Bente most recently held the role of Vice President of Strategic Alliances in Business Development at Insulet Corporation, where he led strategic partnering and collaborations for the world's largest wearable insulin pump company. Before joining Insulet he spent six years at Unilife establishing and scaling the business of novel pre-filled wearable injectors for pharmaceutical customers and 8 years at Medtronic Diabetes designing, developing, and commercializing insulin pumps. Mr. Bente received a BS in Engineering from Harvey Mudd College, an MS in Mechanical Engineering from UCLA, and an MBA from UCLA's Anderson School of Management. On this episode we will hear from Mr. Bente about: His background - how he developed an interest in mechanical engineering and a bit of his path through the bio-medical device segment. The Seventh Sense Biosystems Story including it's founders, investors, mission, and goals. A market overview per "next generation" blood collection technologies with a focus on the TAP technology. A discussion of tele-health, remote diagnostics, and other opportunities related to the future of such tools� in the smart home / smart home care setting - with a focus on Covid-19. Future ideas / Potential "combinatorial" applications with other diagnostic tools and potential consumer applications, such as personalized nutrition and home based genetic analysis. A discussion of mentors and influencers over Rick's career. This interview is in American English. Visit ideaXme: www.radioideaxme.com Credits: Ira Pastor interview video, text, and audio. Follow Ira Pastor on Twitter:@IraSamuelPastor If you liked this interview, be sure to check out ourinterview with Dr. Robert Langer! Follow ideaXme on Twitter:@ideaxm On Instagram:@ideaxme Find ideaXme across the internet including oniTunes, YouTube, SoundCloud,Radio Public,TuneIn Radio,I Heart Radio, Google Podcasts, Spotify and more. ideaXme is a global podcast, creator series and mentor programme. Our mission: Move the human story forward!™ ideaXme Ltd.

A Talk with Culinary Superstar Sam Talbot - Jane's guest today is the celebrated chef, Sam Talbot. Voted "Fan Favorite" on Bravo TV's hit reality show, Top Chef, Sam, who is also a best selling author, is the founding Executive Chef of some of the trendiest restaurants in New York City--and beyond. Aside from being a successful restaurateur and entrepreneur, he has also established himself as the go-to chef for some of Hollywood’s biggest names. Yet with all his acclaim and accomplishments, Sam has had to deal with a very personal physical challenge on a daily basis. Indeed, he was diagnosed with Type 1 diabetes at the age of twelve and has devoted much of his adult years to inspiring the diabetes community to live longer and happier lives. On today's segment, Sam and Jane talk about his new campaign with Medtronic Diabetes and his recently launched, non-profit organization, BEYOND TYPE 1, that aims to show how revolutionary tech can help those living with diabetes avoid the disease's debilitating highs and lows. Listeners will hear Sam's inspirational journey, the relationship between food and health, how diabetes technology makes living with the condition less of a burden, and learn quick tips on how to enjoy food more, and worry a little less. Understanding the impact of food on life and life on food will help everyone feel Better Than Before.

James is joined by Jake Leach, Chief Technology Officer at Dexcom. Jake oversees the development of next generation products and his teams are responsible for delivering best in class glucose monitoring technology paired with an exceptional user experience. Jake joined Dexcom in March 2004 to lead development of sensor electronics which were part of the first generation Dexcom system. Jake has served in various roles within Dexcom including Senior Vice President of R&D, Senior Director of R&D, and Manager of Engineering. From 1996 to 2004, Jake held positions in research and development at MiniMed and subsequently Medtronic Diabetes, focusing on the development of glucose sensing systems. Jake holds a Bachelor of Science degree in Electrical Engineering with a minor in Biomedical Engineering from the University of California, Los Angeles. James and Jake talk about how Jake's background in engineering and his inquisitive mind set him up for a career in medical devices, how MiniMed and Dexcom scaled so fast and why the diabetes-tech space is so exiting right now. www.dexcom.com For more information and content, check out our website www.hs.ventures. You can follow us on Twitter @HSVenture, on Instagram @hs.ventures, on Linkedin at HS. and you can email us at info@hs.live You can get our host, Dr. James Somauroo, at www.jamessomauroo.com and you can follow him on Twitter @jamessomauroo, on Instagram @j_soms and on Linkedin at james-somauroo

About three weeks ago, the U.S. Food and Drug Administration approved the MiniMed 670g, Medtronic's hybrid closed loop system, for people with diabetes over the age of 14. This news has generated a lot of excitement, and also a lot of questions.  I was fortunate enough to connect a little over a week ago with Karrie Hawbaker and Michael Hill of Medtronic Diabetes (which is why then I was saying the approval was two weeks ago), who went on the record about how the 670g works, the new CGM sensor associated with the 670g, and the upgrade pathway for existing Medtronic customers.  Which is still a little murky, but they recognize that every customer is different, and they're willing to talk to you about it.  There's also a little at the end about how Medtronic is leveraging IBM's Watson supercomputer to crunch data. Here then, is everything you want to know about the 670g.  Thanks Karrie and Mike! Reference Material - Click below for more information on this topic: Karrie Hawbaker is Senior Manager of Social Media for Medtronic Diabetes, and Michael Hill is Vice President of Global Marketing in the Intensive Insulin Management business unit at Medtronic: medtronicdiabetes.com If you're an existing Medtronic pumper, and you're interested in upgrading to the 670g in the spring, here is all the information on the Priority Access Program: medtronicdiabetes.com/products/priority-access  

Dr. Francine Kaufman is the chief medical officer for the Diabetes Group at Medtronic. On September 28th, the medical technology company announced a major breakthrough in the treatment of type 1 diabetes. Full podcast notes available at http://ktla.com/frankbuckleyinterviews.

Samantha Arceneaux shares with me how she has helped over 100 people living with type 1 diabetes to successful win their insurance appeals. Can't get your insurance company to give you an insulin pump or CGM??? Sam can! Also, I go crazy talking about United Health Care and Medtronic Diabetes because they are scumbags. Show Notes Check out the NEW www.myOmniPod.com/Demo today! Sam's Blog is here! ***** Let Medtronic Diabetes and United Health Care hear your voice... Tweet at them @MDT_Diabetes @MedtronicCEO @HoomanHakamiMDT @myUHC #MyPumpMyChoice Medtronics BS announcement about how restricting your choice is good for you can be found here... http://www.ardensday.com/blog/pigs ***** The JBP is now available on Google Play! Subscribe to the podcast on iTunes today! My type 1 diabetes parenting blog Arden's Day Listen to the Juicebox Podcast online Read my award winning memoir: Life Is Short, Laundry Is Eternal: Confessions of a Stay-At-Home Dad Follow Scott on Social Media @ArdensDay @JuiceboxPodcast Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.

For people with type I diabetes, the day-to-day management of the disease can be a full-time job involving the monitoring blood glucose levels and injection of insulin. The medical device giant Medtronic has been working toward the development of what it's called an artificial pancreas, a steady improvement of pump and sensor technology to free type I diabetes patients and allow them to think less about the management of their disease. We spoke to Fran Kaufman, chief medical officer of Medtronic Diabetes, about the progress the company has made, its newest technology that is moving towards the market, and how close it is to realizing its vision of an artificial pancreas.

On this episode, host Bernie Borges is joined by Amanda Sheldon. Amanda is Director of Digital Marketing and Communications at Medtronic Diabetes. She is responsible for leading the overall strategy and direction for digital marketing (web/mobile), social media and public relations.   Amanda and her team are passionately focused on creating a great customer experience to build customer loyalty. They create educational and fun content for their customers that results in customer advocacy and referrals to their friends. They work side by side with legal to engage with customers in complete compliance with industry regulations.    Tune in to hear how Amanda and her team are succeeding on their social business journey. Catch the show notes at http://www.socialbusinessengine.com/podcasts/.

Medtronic is the global leader in medical technology – alleviating pain, restoring health and extending the life for millions of people around the world. The Diabetes business at Medtronic (www.medtronicdiabetes.com) is the world leader in advanced diabetes management solutions, including integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems and therapy management software, as well as world-class, 24/7 expert consumer and professional service and support. "Francine R. Kaufman, MD is Chief Medical Officer and Vice President of Global,Clinical and Health Affairs at Medtronic Diabetes. In addition to her role at Medtronic, Dr. Kaufman is a Distinguished Professor Emerita of Pediatrics and Communications at the Keck School of Medicine and the Annenberg School of Communications of the University of Southern California, and an attending physician at Childrens Hospital Los Angeles. Dr. Kaufman has published more than 200 peer-reviewed and invited publications. She is the author of more than 30 books or book chapters."

On this rebroadcast, we revisit our conversation with Amanda Sheldon; Director of Digital Marketing and Communications at Medtronic Diabetes. Amanda originally started in the technology PR world and was able to merge her skills in communication and her love of science & technology to move into the healthcare field. Tune in to hear about her unique relationship with social media, the passion she has for the communities she helped build, and how her team empowers individuals to tell their stories and add value to the lives of others. Working in a regulated industry is challenging and Amanda shares how her team manages the required processes, why active listening is so important and the metrics they use to measure their success in social media.

On today's show we are speaking with Amanda Sheldon; Director of Digital Marketing and Communications at Medtronic Diabetes. Amanda originally started in the technology PR world and was able to merge her skills in communication and her love of science & technology to move into the healthcare field. Tune in to hear about her unique relationship with social media, the passion she has for the communities she helped build, and how her team empowers individuals to tell their stories and add value to the lives of others. Working in a regulated industry is challenging and Amanda shares how her team manages the required processes, why active listening is so important and the metrics they use to measure their success in social media.